<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Partial breast irradiation versus whole breast radiotherapy for early breast cancer - Hickey, BE - 2021 | Cochrane Library</title> <meta content="Partial breast irradiation versus whole breast radiotherapy for early breast cancer - Hickey, BE - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007077.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Partial breast irradiation versus whole breast radiotherapy for early breast cancer - Hickey, BE - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007077.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007077.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Partial breast irradiation versus whole breast radiotherapy for early breast cancer" name="citation_title"/> <meta content="Brigid E Hickey" name="citation_author"/> <meta content="Margot Lehman" name="citation_author"/> <meta content="margot.lehman@health.qld.gov.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD007077.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/08/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007077.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007077.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007077.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Breast Neoplasms [radiotherapy, surgery]; *Carcinoma, Intraductal, Noninfiltrating; Mastectomy; Mastectomy, Segmental; Radiation Dose Hypofractionation" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007077.pub4&amp;doi=10.1002/14651858.CD007077.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007077\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007077\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","ms","ja","fa","fr","pl","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007077.pub4",title:"Partial breast irradiation versus whole breast radiotherapy for early breast cancer",firstPublishedDate:"Aug 30, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007077.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007077.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007077.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007077.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007077.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007077.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007077.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007077.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007077.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007077.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5242 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007077.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-sec-0126"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-sec-0117"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/appendices#CD007077-sec-0131"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/supinfo/CD007077StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/supinfo/CD007077StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Partial breast irradiation versus whole breast radiotherapy for early breast cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/information#CD007077-cr-0004">Brigid E Hickey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007077.pub4/information#CD007077-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Margot Lehman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/information/en#CD007077-sec-0146">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 August 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007077.pub4">https://doi.org/10.1002/14651858.CD007077.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007077-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007077-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007077-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007077-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007077-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007077-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007077-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007077-abs-0001" lang="en"> <section id="CD007077-sec-0001"> <h3 class="title" id="CD007077-sec-0001">Background</h3> <p>Breast‐conserving therapy for women with breast cancer consists of local excision of the tumour (achieving clear margins) followed by radiotherapy (RT). Most true recurrences occur in the same quadrant as the original tumour. Whole breast radiotherapy (WBRT) may not protect against the development of a new primary cancer developing in other quadrants of the breast. In this Cochrane Review, we investigated the delivery of radiation to a limited volume of the breast around the tumour bed (partial breast irradiation (PBI)) sometimes with a shortened treatment duration (accelerated partial breast irradiation (APBI)). </p> </section> <section id="CD007077-sec-0002"> <h3 class="title" id="CD007077-sec-0002">Objectives</h3> <p>To determine whether PBI/APBI is equivalent to or better than conventional or hypofractionated WBRT after breast‐conserving therapy for early‐stage breast cancer. </p> </section> <section id="CD007077-sec-0003"> <h3 class="title" id="CD007077-sec-0003">Search methods</h3> <p>On 27 August 2020, we searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL and three trial databases. We searched for grey literature: OpenGrey (September 2020), reference lists of articles, conference proceedings and published abstracts, and applied no language restrictions. </p> </section> <section id="CD007077-sec-0004"> <h3 class="title" id="CD007077-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) without confounding, that evaluated conservative surgery plus PBI/APBI versus conservative surgery plus WBRT. Published and unpublished trials were eligible. </p> </section> <section id="CD007077-sec-0005"> <h3 class="title" id="CD007077-sec-0005">Data collection and analysis</h3> <p>Two review authors (BH and ML) performed data extraction, used Cochrane's risk of bias tool and resolved any disagreements through discussion, and assessed the certainty of the evidence for main outcomes using GRADE. Main outcomes were local recurrence‐free survival, cosmesis, overall survival, toxicity (subcutaneous fibrosis), cause‐specific survival, distant metastasis‐free survival and subsequent mastectomy. We entered data into Review Manager 5 for analysis. </p> </section> <section id="CD007077-sec-0006"> <h3 class="title" id="CD007077-sec-0006">Main results</h3> <p>We included nine RCTs that enrolled 15,187 women who had invasive breast cancer or ductal carcinoma in‐situ (6.3%) with T1‐2N0‐1M0 Grade I or II unifocal tumours (less than 2 cm or 3 cm or less) treated with breast‐conserving therapy with negative margins. This is the second update of the review and includes two new studies and 4432 more participants. </p> <p>Local recurrence‐free survival is probably slightly reduced (by 3/1000, 95% CI 6 fewer to 0 fewer) with the use of PBI/APBI compared to WBRT (hazard ratio (HR) 1.21, 95% confidence interval (CI) 1.03 to 1.42; 8 studies, 13,168 participants; moderate‐certainty evidence). </p> <p>Cosmesis (physician/nurse‐reported) is probably worse (by 63/1000, 95% CI 35 more to 92 more) with the use of PBI/APBI (odds ratio (OR) 1.57, 95% CI 1.31 to 1.87; 6 studies, 3652 participants; moderate‐certainty evidence). </p> <p>Overall survival is similar (0/1000 fewer, 95% CI 6 fewer to 6 more) with PBI/APBI and WBRT (HR 0.99, 95% CI 0.88 to 1.12; 8 studies, 13,175 participants; high‐certainty evidence). </p> <p>Late radiation toxicity (subcutaneous fibrosis) is probably increased (by 14/1000 more, 95% CI 102 more to 188 more) with PBI/APBI (OR 5.07, 95% CI 3.81 to 6.74; 2 studies, 3011 participants; moderate‐certainty evidence). </p> <p>The use of PBI/APBI probably makes little difference (1/1000 less, 95% CI 6 fewer to 3 more) to cause‐specific survival (HR 1.06, 95% CI 0.83 to 1.36; 7 studies, 9865 participants; moderate‐certainty evidence). </p> <p>We found the use of PBI/APBI compared with WBRT probably makes little or no difference (1/1000 fewer (95% CI 4 fewer to 6 more)) to distant metastasis‐free survival (HR 0.95, 95% CI 0.80 to 1.13; 7 studies, 11,033 participants; moderate‐certainty evidence). </p> <p>We found the use of PBI/APBI in comparison with WBRT makes little or no difference (2/1000 fewer, 95% CI 20 fewer to 20 more) to mastectomy rates (OR 0.98, 95% CI 0.78 to 1.23; 3 studies, 3740 participants, high‐certainty evidence). </p> </section> <section id="CD007077-sec-0007"> <h3 class="title" id="CD007077-sec-0007">Authors' conclusions</h3> <p>It appeared that local recurrence‐free survival is probably worse with PBI/APBI; however, the difference was small and nearly all women remain free of local recurrence. Overall survival is similar with PBI/APBI and WBRT, and we found little to no difference in other oncological outcomes. Some late effects (subcutaneous fibrosis) may be worse with PBI/APBI and its use is probably associated with worse cosmetic outcomes. The limitations of the data currently available mean that we cannot make definitive conclusions about the efficacy and safety or ways to deliver PBI/APBI. We await completion of ongoing trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007077-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007077-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007077-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007077-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007077-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD007077-abs-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007077-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007077-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007077-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007077-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007077-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007077-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007077-abs-0002" lang="en"> <h3>Partial breast irradiation for early breast cancer</h3> <p><b>What is the issue?</b> </p> <p>Breast cancer is the most common cancer that women get.</p> <p>Women with early breast cancer who choose to keep their breast need to have radiotherapy (RT) as well as surgery to remove the cancer to make sure it does not regrow in the breast. RT is treatment with high energy x‐rays. Having RT for breast cancer usually means 15 to 30 visits to the RT department, five times per week. </p> <p>If breast cancer does regrow in the same breast (called local recurrence), it tends to come back in the area it was removed from. Women can also grow a new cancer (new 'elsewhere primary') in another part of the same breast. We are not sure if the RT given to stop cancer regrowth where the first cancer was, stops the growth of 'elsewhere primaries.' </p> <p><b>Why does it matter?</b> </p> <p>We always want to treat the smallest area we can with RT because this means fewer side effects. Treating only part of the breast could mean that RT might be able to be used again in another part of the same breast if needed. New ways of giving RT mean that treating part of the breast can be done with fewer treatments. This is likely to be easier for women and cost less money. </p> <p><b>What did we compare?</b> </p> <p>We asked if giving RT to part of the breast (called partial breast irradiation (PBI)) is as good as giving RT to the whole breast. PBI can be given with a shortened treatment duration (called accelerated partial breast irradiation (APBI)). </p> <p>For this treatment to be acceptable, it would need to control the cancer as well as giving RT to the whole breast does. It would also be important that the PBI gives about the same side effects and breast appearance as treating the whole breast. </p> <p><b>What did we find?</b> </p> <p>We found nine studies, which involved 15,187 women. Our evidence is current to 27 August 2020. Local recurrence is probably slightly more common with APBI/PBI (moderate‐quality evidence) and the breast appearance (scored by doctors and nurses) was probably worse with APBI/PBI (moderate‐quality evidence). There is probably little difference in survival (high‐quality evidence). Late radiation fibrosis (change in breast appearance and feel) is probably increased with APBI/PBI. There are probably few differences in breast cancer‐related deaths and spread of breast cancer around the body with the use of APBI/PBI. The use of APBI/PBI makes little difference to how many women need mastectomy (removal of the whole breast) because of unacceptable late side effects or local recurrence. </p> <p><b>What do our findings mean?</b> </p> <p>This means that at the moment, PBI does not give the same cancer control in the breast as treating the whole breast, but the difference is small. It may cause worse side effects. There are seven big ongoing studies that will be important to answer this question. We hope to have a clearer answer in the next update of this review. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007077-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007077-sec-0126"></div> <h3 class="title" id="CD007077-sec-0127">Implications for practice</h3> <section id="CD007077-sec-0127"> <p>Local recurrence is probably slightly worse when accelerated partial breast irradiation (APBI) or partial breast irradiation (PBI) is used, but the difference is small (approximately 1%). Cosmetic outcome is probably worse with the use of APBI/PBI. APBI/PBI makes little difference to survival, and probably makes little difference to cause‐specific survival, and distant metastasis‐free survival. APBI/PBI makes little or no difference to the mastectomy rate. </p> <p>The limitations of the data currently available mean that we cannot make definitive conclusions about the efficacy and safety or ways to deliver of PBI/APBI. We await completion of ongoing trials. </p> </section> <h3 class="title" id="CD007077-sec-0128">Implications for research</h3> <section id="CD007077-sec-0128"> <p>The ongoing trials will address relevant clinical outcomes. PBI/APBI is a highly technical intervention that is operator dependent and requires careful quality assurance. Interpretation of these trials will require consideration of the quality of the RT delivered, with respect to target definition and treatment verification. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007077-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007077-sec-0008"></div> <div class="table" id="CD007077-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of Findings Table ‐ PBI?APBI compared to WBRT for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PBI/APBI compared to WBRT for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : health problem or population <b>Setting</b> : Academic, tertiary and community practice <b>Intervention</b> : PBI/APBI <b>Comparison</b>: WBRT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with WBRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with PBI/APBI</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Local recurrence‐free survival ‐ total (LR‐FS)<br/>follow up: range 60 months to 103 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 1.21</b><br/>(1.03 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>13168<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a,</sup><sup>b,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>985 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>982 per 1000</b><br/>(979 to 985) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cosmesis, physician/nurse‐reported<br/>assessed with: Harvard scale<br/>follow up: range 60 months to 8.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>138 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>201 per 1000</b><br/>(173 to 230) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.57</b><br/>(1.31 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3652<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>e,</sup><sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Overall survival<br/>follow up: range 60 months to 103 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.99</b><br/>(0.88 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>13175<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH <sup>c,</sup><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>949 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>949 per 1000</b><br/>(943 to 955) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subcutaneous fibrosis (late RT toxicity)<br/>assessed with: EORTC/RTOG CTCAE and NCI Version 3‐4.0<br/>follow up: median 60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>43 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>184 per 1000</b><br/>(145 to 231) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 5.07</b><br/>(3.81 to 6.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3011<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Cause‐specific survival (C‐SS)<br/>follow up: range 60 months to 103 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 1.06</b><br/>(0.83 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9865<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>i,</sup><sup>j,</sup><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>983 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>982 per 1000</b><br/>(977 to 986) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Distant metastasis‐free survival (DM‐FS)<br/>follow up: range 60 months to 72.2 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.95</b><br/>(0.80 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>11033<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>l,</sup><sup>m,</sup><sup>n,</sup><sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>971 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>972 per 1000</b><br/>(967 to 977) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subsequent mastectomy<br/>follow up: median 60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>97 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>95 per 1000</b><br/>(77 to 116) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.98</b><br/>(0.78 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3740<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>HR:</b> Hazard Ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_416473753410884319" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_416473753410884319</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> There was considerable clinical heterogeneity with respect to radiotherapy dose, technique and use of quality assurance procedures. However, the techniques employed delivered a dose that was the same or higher in the APBI/PBI arm than the WBRT arm, which should mean the local recurrence‐free survival is better or at least the same.<br/><b>b.</b> To calculate the control risk for LR‐FS, we used the number free from local recurrence at five years.<br/><b>c.</b> Studies that contributed data for this outcome at five years: Livi, ELIOT, IMPORT, GEC‐ESTRO, Polgar, TARGIT and RAPID.<br/><b>d.</b> Downgraded one level for imprecision: confidence intervals failed to exclude harms that are clinically important and clinically unimportant.<br/><b>e.</b> One study (which contributed 47% of study weight for this outcome) was at low risk of detection bias.<br/><b>f.</b> Studies that contributed data at five years: Polgar, Livi, TARGIT, Rodriguez, RAPID and GEC‐ESTRO.<br/><b>g.</b> Downgraded one level for risk of detection bias and heterogeneity.<br/><b>h.</b> To calculate the control risk for overall survival, we used the number alive at five years.<br/><b>i.</b> To calculate the control risk for cause‐specific survival, we used the number free from breast cancer death at five years.<br/><b>j.</b> Studies that contributed data at five years: Livi, ELIOT, IMPORT, GEC‐ESTRO, Polgar and RAPID.<br/><b>k.</b> Downgraded one level for detection bias and imprecision: fewer than 300 events contributed to this outcome and confidence intervals failed to exclude both clinically important benefits and harms.<br/><b>l.</b> Confidence intervals failed to exclude clinically important benefits and unimportant harms.<br/><b>m.</b> Five studies contributed data to control event‐free rate at five years (ELIOT, GEC‐ESTRO, IMPORT, Livi and Polgar).<br/><b>n.</b> To calculate the control risk for distant metastasis‐free survival, we used the number free from metastasis at five years.<br/><b>o.</b> Downgraded one level for detection bias and imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007077-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007077-sec-0009"></div> <section id="CD007077-sec-0010"> <h3 class="title" id="CD007077-sec-0010">Description of the condition</h3> <p>Breast cancer is the most common cancer occurring in women. One in eight women living in the US, Australia and the UK has a lifetime risk of being diagnosed with breast cancer (<a href="./references#CD007077-bbs2-0034" title="Cancer Council Australia. Breast cancer. www.cancer.org.au/about-cancer/types-of-cancer/breast-cancer/#:~:text=In%202015%2C%2016%2C852%20women%20and,year%20survival%20rate%20is%2091%25 (accessed 12 August 2020).">Cancer 2020</a>; <a href="./references#CD007077-bbs2-0057" title="HowladerN , NooneAM , KrapchoM , NeymanN , AminouR , WaldronW , et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations). seer.cancer.gov/csr/1975_2009_pops09/ (accessed 20 March 2013).">Howlader 2009</a>; <a href="./references#CD007077-bbs2-0074" title="Office of National Statistics. Breast cancer in England, 2010 release. www.ons.gov.uk/ons/rel/cancer-unit/breast-cancer-in-england/2010/sum-1.html (accessed 20 March 2013).">ONS 2010</a>). Breast cancer is the second most common cause of cancer death in women. </p> <p>Historically, mastectomy was the recommended therapeutic option for all stages of breast cancer. However, large randomised controlled trials (RCTs) demonstrated equivalent survival for women with early‐stage disease (Stages I, II) whether they were treated with breast‐conserving therapy or mastectomy (<a href="./references#CD007077-bbs2-0040" title="Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomised trial. New England Journal of Medicine1995;333(22):1444-55.">EBCTCG 1995</a>; <a href="./references#CD007077-bbs2-0042" title="FisherB , AndersonS , RedmondCK , WolmarkN , WickerhamDL , CroninWM . Re-analysis and results after 12 years of follow-up in a randomised clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. New England Journal of Medicine1995;333(22):1456-61.">Fisher 1995</a>; <a href="./references#CD007077-bbs2-0043" title="FisherB , AndersonS , BryantJ , MargoleseRG , DeutschM , FisherER , et al. Twenty-year follow-up of a randomised trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine2002;347(16):1233-41.">Fisher 2002</a>; <a href="./references#CD007077-bbs2-0059" title="JacobsonJA , DanforthDN , CowanKH , d'AngeloT , SteinbergSM , PierceL , et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. New England Journal of Medicine1995;332(14):907-11.">Jacobson 1995</a>; <a href="./references#CD007077-bbs2-0079" title="PoggiMM , DanforthDN , SciutoLC , SmithSL , SteinbergSM , LiewehrDJ , et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomised Trial. Cancer2003;98(4):697-702.">Poggi 2003</a>; <a href="./references#CD007077-bbs2-0100" title="vanDongenJA , VoogdAC , FentimanIS , LegrandC , SylvesterRJ , TongD , et al. Long-term results of a randomised trial comparing breast-conserving therapy with mastectomy: European Organisation for Research and Treatment of Cancer 10801 trial. Journal of the National Cancer Institute2000;92(14):1143-50.">van Dongen 2000</a>; <a href="./references#CD007077-bbs2-0101" title="VeronesiU , SalvadoriB , LuiniA , GrecoM , SaccozziR , delVecchioM , et al. Breast conservation is a safe method in patients with a small cancer of the breast. Long-term results of three randomised trial on 1973 patients. European Journal of Cancer1995;31(10):1574-9.">Veronesi 1995</a>; <a href="./references#CD007077-bbs2-0102" title="VeronesiU , CascinelliN , MarianiL , GrecoM , SaccozziR , LuiniA , et al. Twenty-year follow-up of a randomised study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New England Journal of Medicine2002;347(16):1227-32.">Veronesi 2002</a>). Consequently, breast conservation has become the preferred management option for these women. </p> <p>Breast‐conserving therapy consists of local excision of the tumour (achieving clear margins) followed by radiotherapy (RT). RT is given to sterilise tumour cells that may remain after surgery. This practice is supported by data from detailed pathological examination of mastectomy specimens where residual tumour was found more than 2 cm from the original tumour in 41% of participants (<a href="./references#CD007077-bbs2-0056" title="HollandR , VelingSH , MravunacM , HendriksJH . Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer1985;56(5):979-90.">Holland 1985</a>). Conventional RT delivers 45 Gray (Gy) to 50 Gy to the whole breast over five weeks frequently followed by a boost to the tumour bed (the most likely site of residual tumour cells) of 10 Gy to 16 Gy over one to two weeks. This prolonged duration of treatment negatively impacts on quality of life (<a href="./references#CD007077-bbs2-0107" title="WhelanTJ , LevineM , JulianJ , KirkbrideP , SkingleyP . The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomised trial. Ontario Clinical Oncology Group. Cancer2000;88(10):2260-6.">Whelan 2000</a>), and contributes to the higher mastectomy rates observed in women residing in rural and remote areas who wish to avoid being away from home and family for extended periods (<a href="./references#CD007077-bbs2-0086" title="SchroenAT , BreninDA , KellyMD , KnaussWA , Slinguff CL Jr. Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. Journal of Clinical Oncology2005;23(28):7074-80.">Schroen 2005</a>). </p> <p>Hypofractionated whole breast radiotherapy (WBRT) regimens, in which 40 Gy to 42.5 Gy is delivered to the whole breast over three to four weeks using a larger radiation dose with each treatment have been investigated. Compared to conventional WBRT, hypofractionated WBRT results in no difference in breast recurrence rates at five and 10 years, no difference in overall survival (OS) and an improvement in cosmetic outcomes (<a href="./references#CD007077-bbs2-0092" title="START Trialists' Group, BentzenSM , AgrawalRK , AirdEG , BarrettJM , Barrett-LeePJ , BlissJM , et al. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331-41.">START 2008</a>; <a href="./references#CD007077-bbs2-0093" title="START Trialists' Group, BentzenSM , AgrawalRK , AirdEG , BarrettJM , Barrett-LeePJ , BentzenSM , et al. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet2008;371(9618):1098-107.">START B 2008</a>; <a href="./references#CD007077-bbs2-0108" title="WhelanT , MacKenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143-50.">Whelan 2002</a>). </p> <p>RCTs have shown that the addition of conventional or hypofractionated WBRT to local excision decreases ipsilateral breast (same breast) recurrence rates from 30% to 40% (<a href="./references#CD007077-bbs2-0042" title="FisherB , AndersonS , RedmondCK , WolmarkN , WickerhamDL , CroninWM . Re-analysis and results after 12 years of follow-up in a randomised clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. New England Journal of Medicine1995;333(22):1456-61.">Fisher 1995</a>; <a href="./references#CD007077-bbs2-0043" title="FisherB , AndersonS , BryantJ , MargoleseRG , DeutschM , FisherER , et al. Twenty-year follow-up of a randomised trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine2002;347(16):1233-41.">Fisher 2002</a>; <a href="./references#CD007077-bbs2-0045" title="FreemanCR , BelliveauNJ , KimTH , BoivinJF . Limited surgery with or without radiotherapy for early breast carcinoma. Journal Canadian Association of Radiology1981;32(2):125-8.">Freeman 1981</a>; <a href="./references#CD007077-bbs2-0064" title="LagiosMD , RichardsVE , RoseMR , YeeE . Segmental mastectomy without radiotherapy. Short-term follow-up. Cancer1983;52(11):2173-9.">Lagios 1983</a>; <a href="./references#CD007077-bbs2-0070" title="MontgomeryAC , GreeningWP , LeveneAL . Clinical study of recurrence rate and survival time of patients with carcinoma of the breast treated by biopsy excision without any other therapy. Journal of the Royal Society of Medicine1978;71(5):339-42.">Montgomery 1978</a>) to 10% to 20% with 10 to 15 years of follow‐up (<a href="./references#CD007077-bbs2-0042" title="FisherB , AndersonS , RedmondCK , WolmarkN , WickerhamDL , CroninWM . Re-analysis and results after 12 years of follow-up in a randomised clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. New England Journal of Medicine1995;333(22):1456-61.">Fisher 1995</a>; <a href="./references#CD007077-bbs2-0043" title="FisherB , AndersonS , BryantJ , MargoleseRG , DeutschM , FisherER , et al. Twenty-year follow-up of a randomised trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine2002;347(16):1233-41.">Fisher 2002</a>). Modern breast‐conserving therapy with postoperative WBRT achieves local control rates of 3.3% to 3.4% at five years and 5.2% to 6.7% at 10 years (<a href="./references#CD007077-bbs2-0052" title="HavilandJS , OwenJR , DewarJA , AgrawalRK , BarrettJ , Barrett-LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncology2013;14:1086-94.">Haviland 2013</a>). With careful patient selection (aged 65 years or greater, T1‐2 tumours, tumour not greater than 3 cm, margin negative, oestrogen receptor positive and all receiving tamoxifen), surgery alone can achieve local recurrence rates of 4.1% at five years (<a href="./references#CD007077-bbs2-0063" title="KunklerIH , WilliamsLJ , JackWJ , CameronDA , DixonJM , PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncology2015;16(3):266-73.">Kunkler 2015</a>). An ipsilateral recurrence can either be a true recurrence of the original cancer (typically arising in the same quadrant as the original tumour and known as local recurrence) or a second primary tumour developing elsewhere in that same breast. Studies evaluating ipsilateral breast tumour recurrence patterns showed that new primaries increasingly contribute to the rate of recurrence after five to eight years while true recurrence rates stabilise (<a href="./references#CD007077-bbs2-0062" title="KraussDJ , KestinLL , MitchellC , MartinezAA , ViciniFA . Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications. International Journal of Radiation Oncology, Biology, Physics2004;60(3):731-40.">Krauss 2004</a>; <a href="./references#CD007077-bbs2-0088" title="SmithTE , LeeD , TurnerBC , CarterD , HafftyB . True recurrence vs new primary ipsilateral breast tumour relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses and therapeutic management. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1281-9.">Smith 2000</a>). If WBRT was successful in preventing the recurrence of new primary cancers, the rate of such cancers in the treated breast should be lower than the rate of development of cancers in the other breast (contralateral breast cancer). Studies of ipsilateral breast tumour recurrence patterns have not found this (<a href="./references#CD007077-bbs2-0062" title="KraussDJ , KestinLL , MitchellC , MartinezAA , ViciniFA . Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications. International Journal of Radiation Oncology, Biology, Physics2004;60(3):731-40.">Krauss 2004</a>; <a href="./references#CD007077-bbs2-0088" title="SmithTE , LeeD , TurnerBC , CarterD , HafftyB . True recurrence vs new primary ipsilateral breast tumour relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses and therapeutic management. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1281-9.">Smith 2000</a>). Furthermore, studies examining primary and re‐excision pathological specimens removed at the time of breast‐conserving surgery revealed residual tumour 15 mm or less from the primary tumour in 91% of the specimens (<a href="./references#CD007077-bbs2-0105" title="WallnerP , ArthurD , BartelinkH . Workshop on partial breast irradiation: state of the art and the science. Bethesda MD December 8th-10th 2002. Journal of the National Cancer Institute2004;96:175-84.">Wallner 2004</a>). </p> <p>Thus, as most true recurrences occur in the same quadrant as the original tumour and as WBRT does not appear to protect against the development of new primary cancer, investigators are examining the role of partial breast irradiation (PBI). </p> </section> <section id="CD007077-sec-0011"> <h3 class="title" id="CD007077-sec-0011">Description of the intervention</h3> <p>PBI (also known as less than WBRT) refers to irradiation of a limited volume of breast tissue around the tumour bed. It may be achieved by any of the following techniques. </p> <p> <ol id="CD007077-list-0001"> <li> <p>Intracavitary brachytherapy or MammoSite (applying radioactive sources directly into the cavity left after surgical removal of the tumour either at the time of surgery or at a later date, the latter requiring a second procedure). </p> </li> <li> <p>Interstitial brachytherapy (inserting catheters into the surgical cavity and surrounding tissue to temporarily deliver radioactive sources). </p> </li> <li> <p>Intraoperative techniques using electrons or x‐rays at 50 kilovoltage peak (kVp) (using a dedicated machine to deliver a very localised radiation dose to the surgical cavity in the operating room or by moving the person with an open wound to the radiation machine, which may be in a different part of the hospital). </p> </li> <li> <p>External beam radiotherapy (EBRT) using either three‐dimensional conformal radiotherapy (3D‐CRT) (EBRT delivered in the postoperative setting to a volume of breast tissue around the tumour cavity using a standard linear accelerator in a radiation oncology department) or other methods. </p> </li> </ol> </p> <p>Conventional RT typically delivers a radiation dose of 2 Gy with each treatment. Some PBI techniques deliver a larger than standard dose of radiation with each treatment, allowing the overall duration of treatment to be shortened. This is termed accelerated partial breast irradiation (APBI). </p> </section> <section id="CD007077-sec-0012"> <h3 class="title" id="CD007077-sec-0012">How the intervention might work</h3> <p>PBI/APBI will only be of benefit if it confers the same local control benefit as standard WBRT with acceptable toxicity and cosmesis. Currently, some authorities consider PBI/APBI to be an experimental therapy (Clinical Evidence). The National Comprehensive Cancer Network (<a href="./references#CD007077-bbs2-0071" title="National Comprehensive Cancer Network. NCCN guidelines version 2.2015 invasive breast cancer. www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed 7 November 2015).">NCCN</a>) state, "Preliminary studies of APBI suggest rates of local control in patients with early‐stage breast cancer may be comparable to those treated with WBRT. Follow‐up, however is limited and studies are ongoing" (<a href="./references#CD007077-bbs2-0071" title="National Comprehensive Cancer Network. NCCN guidelines version 2.2015 invasive breast cancer. www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed 7 November 2015).">NCCN</a>). Because this technique has been widely adopted outside the context of clinical trials, published guidelines exist that identify women with early breast cancer for whom this technique may be safe. For those women ineligible for a trial, carefully selected women with early breast cancer may be offered PBI/APBI (<a href="./references#CD007077-bbs2-0030" title="BellonJR , HarrisEE , ArthurDW , BaileyL , CareyL , GoyalS , et al. ACR Appropriateness Criteria® conservative surgery and radiation – stage I and II breast carcinoma: expert panel on radiation oncology: breast. Breast Journal2011;17(5):448-55.">Bellon 2011</a>; <a href="./references#CD007077-bbs2-0080" title="PolgárC , Van LimbergenE , PötterR , KovácsG , PoloA , LyczekJ , et al. Patient selection for accelerated partial-breast irradiation (PBI/APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiotherapy and Oncology2010;94(3):264-73.">Polgár 2010</a>; <a href="./references#CD007077-bbs2-0089" title="SmithBD , ArthurDW , BuchholzTA , HafftyBG , HahnCA , HardenberghPH , et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). International Journal of Radiation Oncology, Biology, Physics2009;74(4):987-1001.">Smith 2009</a>). </p> <p>PBI/APBI has several potential advantages including:</p> <p> <ol id="CD007077-list-0002"> <li> <p>a reduction in treatment‐related toxicities, as a smaller volume of breast tissue is irradiated; </p> </li> <li> <p>increased utilisation of breast conservation;</p> </li> <li> <p>a reduction in RT waiting times; a reduction in the overall treatment duration of a common malignancy has the potential to substantially impact on RT waiting times in countries with strained resources (including the UK, Canada, Australia and New Zealand); </p> </li> <li> <p>a greater chance of preserving the breast should a recurrence occur elsewhere in the breast; </p> </li> <li> <p>easier integration with chemotherapy schedules because RT time will be shorter, thus avoiding delays. </p> </li> </ol> </p> <p>PBI/APBI has several potential disadvantages including:</p> <p> <ol id="CD007077-list-0003"> <li> <p>an increased risk of local recurrence due to geographic miss. This is either because treatment was delivered before full pathological examination was obtained or because of difficulty in reproducing the target volume (the tissue that needed to be treated with RT) daily; </p> </li> <li> <p>increased late toxicity. The late effects of radiation are dependent on the dose of radiation given at each treatment and, as PBI/APBI delivers a large radiation dose per fraction, late toxicity may be increased with resultant poor cosmetic outcome or breast appearance (cosmesis); </p> </li> <li> <p>more patient inconvenience as some techniques may require a second anaesthetic or a further invasive procedure; </p> </li> <li> <p>several techniques (e.g. interstitial and intracavitary brachytherapy) require operator expertise and specialised equipment that may not be available in all centres; </p> </li> <li> <p>invasive techniques of delivering PBI/APBI (e.g. interstitial and intracavitary brachytherapy) may be associated with toxicity such as infection and delays in wound healing. Scarring following insertion of interstitial brachytherapy catheters can negatively impact on cosmetic appearance. </p> </li> </ol> </p> </section> <section id="CD007077-sec-0013"> <h3 class="title" id="CD007077-sec-0013">Why it is important to do this review</h3> <p>PBI/APBI has the potential to change the pattern of practice for a common malignancy and thereby impact on resource utilisation, patient satisfaction and quality of life. However, as PBI/APBI is currently an experimental therapy, it must be thoroughly evaluated before being adopted as the new standard of care for early‐stage breast cancer. PBI/APBI can be recommended if it is as effective or better than conventional or hypofractionated WBRT for cancer‐related outcomes (local relapse‐free survival (LR‐FS), survival, breast cancer‐specific survival and metastasis‐free survival) as well as patient‐orientated outcomes (cosmesis, quality of life and consumer preference). We found one systematic review that concluded, "The data on PBI/APBI compared to whole‐breast irradiation are insufficient to draw any conclusions about the relative effectiveness of these modalities" (<a href="./references#CD007077-bbs2-0032" title="BlueCross BlueShield Association. Accelerated partial breast irradiation as sole radiotherapy after breast-conserving surgery for early stage breast cancer – executive summary. Technology Assessment Central Assessment Program2007;22(4):1-4.">BlueCross BlueShield</a>). The fact that the benefit versus risk profile of PBI/APBI is currently unknown makes it an ideal topic for a systematic review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007077-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007077-sec-0014"></div> <p>To determine whether PBI/APBI is equivalent to or better than conventional or hypofractionated WBRT after breast‐conserving therapy for early‐stage breast cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007077-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007077-sec-0015"></div> <section id="CD007077-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007077-sec-0017"> <h4 class="title">Types of studies</h4> <p>RCTs evaluating conservative surgery plus PBI/APBI versus conservative surgery plus WBRT. The comparisons had to be unconfounded (i.e. treatments given to the randomised groups had to differ only in relation to the volume of the breast irradiated). Trials incorporating adjuvant treatments, such as chemotherapy, monoclonal antibodies or hormonal therapy, were eligible if the RCT applied these other treatments in exactly the same way to both groups. Published and unpublished studies were eligible. </p> <p>We did not consider studies in which PBI was used as a boost following conventional EBRT for inclusion. </p> </section> <section id="CD007077-sec-0018"> <h4 class="title">Types of participants</h4> <p>Women with histologically confirmed early‐stage breast cancer who had conservative surgery. Early breast cancer included tumours classified as American Joint Committee on Cancer (AJCC) Stage T1‐2N0‐1M0 (<a href="./references#CD007077-bbs2-0044" title="FlemingI , CooperJ , HensonDE , HutterR , KennedyB , MurphyG , et al. AJCC Cancer Staging Manual. 5th edition. Philadelphia (PA): Lippincott-Raven, 1997.">Fleming 1997</a>). Surgery could include lumpectomy and wide local excision or quadrantectomy, with or without axillary dissection, axillary sampling or sentinel node biopsy. Women with a previous diagnosis of breast cancer were not eligible for inclusion. </p> </section> <section id="CD007077-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Radiation delivered to the partial breast (PBI) and PBI using larger than standard radiation dose per fraction such that the overall treatment time was reduced (APBI). We considered any method of PBI/APBI delivery consistent with contemporary practice, including, but not limited to, intracavitary brachytherapy or MammoSite, interstitial brachytherapy, intraoperative techniques such as electrons or x‐rays at 50 kVp or EBRT using 3D‐CRT or other methods. Conventional breast RT is delivered to the whole breast with or without the supraclavicular fossa and axilla, using standard fractionation (1.8 Gy to 3.0 Gy per fraction) to deliver a total of 40 Gy to 61 Gy at the reference point. Treatment could include a boost (using electrons, interstitial therapy, EBRT or new techniques). </p> </section> <section id="CD007077-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD007077-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>1.1 Local recurrence‐free survival (LR‐FS) in the ipsilateral breast. We defined local recurrence as a recurrence of the same histological type of cancer within the same quadrant of the breast as the primary cancer. </p> <p>1.2 Cosmesis (cosmetic outcome or breast appearance).</p> </section> <section id="CD007077-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>2.1 Overall survival (OS, time from date of randomisation to death from any cause, or number of deaths from any cause). </p> <p>2.2 Toxicity (including acute and late effects of RT, chemotherapy‐related toxicity and surgical toxicity; individual protocol‐based definitions). </p> <p>2.3 New primary tumours in ipsilateral breast, 'elsewhere primaries.' We defined a new primary as a lesion arising in a quadrant of the breast that was different from the original cancer or a tumour of a different histological subtype occurring anywhere within the breast. </p> <p>2.4 Cause‐specific survival (C‐SS, deaths due to breast cancer at five years).</p> <p>2.5 Distant metastasis‐free survival (DM‐FS, in isolation or at the same time as local recurrence (the occurrence of metastases at five years)). </p> <p>2.6 Relapse‐free survival (R‐FS, length of time after treatment during which there was no recurrence). Recurrence referred to breast cancer in the ipsilateral breast or elsewhere in the body, excluding a new breast cancer in the contralateral breast. </p> <p>2.7 Locoregional recurrence‐free survival (L‐RR‐FS, comprised local recurrence, 'elsewhere' ipsilateral breast primaries (a new primary cancer in the same breast) and regional nodal relapse). </p> <p>2.8 Subsequent mastectomy (ipsilateral partial mastectomy, modified radical mastectomy or radical mastectomy). </p> <p>2.9 Compliance, defined as the number of women who commenced treatment with PBI/APBI or conventional EBRT and completed the treatment course. </p> <p>2.10 Costs (monetary costs of PBI versus EBRT) to women, government and insurance companies. </p> <p>2.11 Quality of life (using trial‐specific instruments). The effects of PBI/APBI and EBRT on global quality of life and the physical, emotional and psychological domains. </p> <p>2.12 Consumer preference, that is, did women prefer PBI/APBI or WBRT given the advantages and disadvantages of each approach. </p> </section> </section> </section> <section id="CD007077-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007077-sec-0024"> <h4 class="title">Electronic searches</h4> <section id="CD007077-sec-0025"> <h5 class="title">Electronic databases</h5> <p>We searched the following databases:</p> <p> <ol id="CD007077-list-0004"> <li> <p>Cochrane Breast Cancer Group Specialised Register (27 August 2020). Details of search strategies used to identify studies and the procedure used to code references are outlined in the group's module (<a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/BREASTCA/frame.html" target="_blank">Cochrane Breast Cancer Group</a>). We extracted studies on the specialised register with keywords 'early breast cancer', 'radiotherapy', 'partial breast irradiation', 'whole breast irradiation', 'whole breast radiotherapy', 'brachytherapy', 'high‐dose‐rate brachytherapy', 'accelerated partial breast irradiation', 'tumour bed boost', 'sole tumour bed irradiation', 'MammoSite', 'radiotherapy', 'PBI', 'APBI' and 'interstitial brachytherapy' for consideration; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Library (2020, Issue 8; <a href="./appendices#CD007077-sec-0132">Appendix 1</a>); </p> </li> <li> <p>MEDLINE via Ovid SP (January 1966 to 27 August 2020; <a href="./appendices#CD007077-sec-0133">Appendix 2</a>); </p> </li> <li> <p>Embase via Ovid SP (1980 to 27 August 2020; <a href="./appendices#CD007077-sec-0134">Appendix 3</a>); </p> </li> <li> <p>CINAHL via EBSCO (1981 to 27 August 2020; <a href="./appendices#CD007077-sec-0135">Appendix 4</a>); </p> </li> </ol> </p> <p>We modified the MEDLINE search strategy to search the other databases, without language restrictions (<a href="./appendices#CD007077-sec-0133">Appendix 2</a>). </p> </section> <section id="CD007077-sec-0026"> <h5 class="title">Unpublished literature</h5> <p>We searched following registers for ongoing clinical trials:</p> <p> <ol id="CD007077-list-0005"> <li> <p>International Standard Randomised Controlled Trial Number Register (<a href="http://www.controlled-trials.com/isrctn" target="_blank">www.controlled-trials.com/isrctn</a>) (7 September 2020); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) search portal (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">apps.who.int/trialsearch/Default.aspx</a>) (27 August 2020; <a href="./appendices#CD007077-sec-0136">Appendix 5</a>); </p> </li> <li> <p>US clinical trials registry (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (27 August 2020; <a href="./appendices#CD007077-sec-0139">Appendix 6</a>). </p> </li> </ol> </p> </section> <section id="CD007077-sec-0027"> <h5 class="title">Grey literature</h5> <p>We checked OpenGrey (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>) (7 September 2020; <a href="./appendices#CD007077-sec-0142">Appendix 7</a>). </p> </section> </section> <section id="CD007077-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We contacted researchers located from the grey literature and unpublished literature to ask if they were aware of any other trials on this topic. We contacted the <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> authors on 15 October 2012 for more information. We contacted the <a href="./references#CD007077-bbs2-0019" title="MeduriB , BaldisseraA , GaleandroM , DoniniE , TolentoG , GiacobazziP . OC-0568: accelerated PBI vs standard radiotherapy (IRMA trial): interim cosmetic and toxicity results. Radiotherapy and Oncology2017;123(S1):S303. NCT01803958. Breast cancer with low risk of local recurrence: partial and accelerated radiation with three-dimensional conformal radiotherapy (3DCRT) vs. standard radiotherapy after conserving surgery (phase III study). clinicaltrials.gov/ct2/show/NCT01803958 (first received 4 March 2013). ">IRMA</a> authors on 2 October 2012 and they supplied us with the trial protocol. We contacted the authors of <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> on 24 August 2013; we gratefully received and incorporated data from the authors of <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> in November 2013. </p> <section id="CD007077-sec-0029"> <h5 class="title">Handsearching</h5> <p>We handsearched several conference proceedings and published abstracts including:</p> <p> <ol id="CD007077-list-0006"> <li> <p>Adjuvant Therapy for Primary Breast Cancer International Conference (2001);</p> </li> <li> <p>Primary Therapy of Early Breast Cancer (2001 and 2003);</p> </li> <li> <p>6th and 7th Nottingham International Breast Cancer Meeting Conference Reports;</p> </li> <li> <p>23rd and 24th Congress of the International Association for Breast Cancer Research;</p> </li> <li> <p>3rd and 4th Perspectives in Breast Cancer Conference Reports;</p> </li> <li> <p>26th and 27th Annual San Antonio Breast Cancer Symposium;</p> </li> <li> <p>4th European Breast Cancer Conference;</p> </li> <li> <p>94th and 95th American Association of Cancer Research;</p> </li> <li> <p>American Society for Clinical Oncology (<a href="./references#CD007077-bbs2-0029" title="Anonymous. LENT SOMA tables. Radiotherapy and Oncology1995;35:17-60.">Anon 1995</a> to 2005; 2012 to 2016); </p> </li> <li> <p>European Society for Therapeutic and Radiation Oncology (1990, 1993, 2000 to 2010, 2012 to 2018); </p> </li> <li> <p>5th and 6th Milan Breast Cancer Conference;</p> </li> <li> <p>Australian Breast Cancer Conference (2004);</p> </li> <li> <p>27th and 28th Annual Symposium of the American Society of Breast Disease;</p> </li> <li> <p>Centers for Disease Control and Prevention (CDC) Cancer Conference (2003);</p> </li> <li> <p>Radiotherapy and Oncology: Proceedings of World Congress of Brachytherapy 2012.</p> </li> </ol> </p> </section> </section> </section> <section id="CD007077-sec-0030"> <h3 class="title" id="CD007077-sec-0030">Data collection and analysis</h3> <section id="CD007077-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ML and BH) checked the titles and abstracts retrieved by the searches, and removed duplicate records. Each review author independently assessed the full text of the studies thought relevant to the review and we resolved any differences in assessment by discussion. We performed trial assessments with the results masked. In cases where data were limited or information on trial methods was limited, we requested further information from the trial authors. </p> </section> <section id="CD007077-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (ML and BH) performed data extraction and resolved disagreements through discussion. We entered data into Review Manager Web for analysis (<a href="./references#CD007077-bbs2-0083" title="Review Manager Web (RevMan Web). Version 5.2. The Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web 2019</a>). Where possible, we extracted data on tumour stage, nodal status, margin status, receptor status, hormonal manipulation, treatment allocation and surgery performed. The information extracted on RT included overall treatment time, radiation dose, dose per fraction and method of PBI. We extracted outcome data on local recurrence, deaths (all‐cause and breast cancer deaths), new ipsilateral primaries, mastectomy rate, distant metastases, treatment‐related toxicity (including that related to acute and late effects of RT and to surgery), cosmesis, costs of treatment, consumer preference and quality of life. </p> <p>We derived data for OS, LR‐FS, DM‐FS, disease‐free survival and C‐SS from information in the text (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>), and data received from trial authors (<a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>). Trial authors of <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> provided the hazard ratios (HR), 95% confidence intervals (CI) and P values, together with the number of events with further follow‐up. We used the spreadsheet developed by Matthew Sydes (<a href="./references#CD007077-bbs2-0095" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(16):1-16.">Tierney 2007</a>) to derive O‐E (observed minus expected events) and variance using the number of events, HRs, P values where available or calculated using the Review Manager Web calculator (<a href="./references#CD007077-bbs2-0083" title="Review Manager Web (RevMan Web). Version 5.2. The Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web 2019</a>). Although there were data for L‐RR‐FS for <a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>, we did not include them in the analysis because some women were treated with regional nodal RT. </p> <p>We converted the radiation doses to the equivalent dose in 2 Gy fractions (EQD<sub>2</sub>) (<a href="./references#CD007077-bbs2-0067" title="MaciejewskiB , TaylorJM , WithersHR . Alpha/beta value and the importance of size of dose per fraction for late complications of the supraglottic larynx. Radiotherapy and Oncology1986;7(4):323-6.">Maciejewski 1986</a>; <a href="./references#CD007077-bbs2-0110" title="WithersHR , Thames HD Jr, PetersLJ . A new isoeffect curve for change in dose per fraction. Radiotherapy and Oncology1983;1(2):187-91.">Withers 1983</a>), using the formula: EQD<sub>2</sub> = D [d + (alpha/beta/2 + alpha/beta)], where D = total dose, d = dose per fraction and alpha/beta = 4 Gy (<a href="./references#CD007077-bbs2-0075" title="OwenJR , AshtonA , BlissJM , HomewoodJ , HarperC , HansonJ , et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncology2006;7(6):467-71.">Owen 2006</a>). This was to facilitate comparison of radiation doses given at differing dose per fraction. </p> <p>We plan to convert brachytherapy (radiation sources applied directly to the body) to the biological equivalent dose (BED) using the method of <a href="./references#CD007077-bbs2-0094" title="StittJA , FowlerJF , ThomadsenBR , BuchlerDA , PaliwalBP , KinsellaTJ . High dose rate intracavitary brachytherapy for carcinoma of the cervix: the Madison System 1: clinical and radiobiological considerations. International Journal of Radiation Oncology, Biology, Physics1992;24(2):335-48.">Stitt 1992</a> should it be necessary to pool brachytherapy data in updates of this review. </p> <p>Studies reported global cosmetic outcome using the Harvard Cosmetic Score (<a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>), the European Organisation for Research and Treatment of Cancer (EORTC) Cosmetic rating System for Breast Cancer) (<a href="./references#CD007077-bbs2-0026" title="AaronsonNK , BartelinkH , vanDongenJA , vanDamFS . Evaluation of breast conserving therapy: clinical, methodological and psychological perspectives. European Journal of Surgery1998;14:133-40.">Aaronson 1998</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>), and a software program (<a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). These were all four‐point scales; the results were dichotomised into good/excellent and fair/poor, with occurrence of fair/poor being counted as 'events' (<a href="#CD007077-tbl-0002">Table 1</a>). </p> <div class="table" id="CD007077-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Harvard Cosmetic Score</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cosmetic score</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excellent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> </tr> </tbody> </table> </div> <p>One study reported telangiectasia (using NCI CTCAE Version 3.0 (National Cancer Institute Common Terminology Criteria for Adverse Events); also a three‐point scale)(<a href="./references#CD007077-bbs2-0072" title="Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (accessed 29 July 2015).">NCI</a>): we recorded any women with Grade 2 or higher toxicity as having events (<a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>). For acute and late RT toxicity, we considered the Grade 2 or greater toxicity in NCI CTCAE Version 3.0, 4.0 and EORTC/RTOG CTC (European Organisation for Research and Treatment of Cancer/Research and Treatment of Cancer Common Toxicity Criteria); all included the same clinical events, so summated these data (<a href="#CD007077-tbl-0003">Table 2</a>; <a href="#CD007077-tbl-0004">Table 3</a>; <a href="#CD007077-tbl-0005">Table 4</a>; <a href="#CD007077-tbl-0006">Table 5</a>). </p> <div class="table" id="CD007077-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">EORTC/RTOG CTCAE</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>RTOG CTC</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade II</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade III</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade IV</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follicular, faint or dull erythema/epilation/dry desquamation/decreased sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tender or bright erythema, patchy moist desquamation/moderate oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confluent, moist desquamation other than skin folds, pitting oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulceration, haemorrhage, necrosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late skin toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slight atrophy, pigmentation change, some hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patchy atrophy, moderate telangiectasia, total hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marked atrophy, gross telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulceration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late subcutaneous fibrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slight induration, loss of subcutaneous fat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate fibrosis (asymptomatic)</p> <p>&lt; 10% linear field contraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe induration, loss of subcutaneous tissue, linear contraction &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulceration</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organisation for Research and Treatment of Cancer; RTOG CTC: Radiation Therapy Oncology Group Common Toxicity Criteria. </p> </div> </div> <div class="table" id="CD007077-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">NCI CTC 3.0</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Toxicity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade 4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration (subcutaneous fibrosis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased density on palpation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate increase in density, not interfering with ADL; marked increase in density and firmness on palpation with or without minimal retraction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysfunction interfering with ADL; very marked density, retraction or fixation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many and confluent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain mild, not interfering with function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate pain; pain or analgesics interfering with function, but not with ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe pain; pain or analgesics interfering with ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADL: activities of daily living; NCI CTC: National Cancer Institute Common Toxicity Criteria. </p> </div> </div> <div class="table" id="CD007077-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">EORTC/RTOG CTCAE Version 3.0</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade II</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade III</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade IV</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade V</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild, not interfering with function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate/analgesics, interferes with function, but not ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe or interferes with ADL, or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many or confluent, or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute skin toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faint erythema or dry desquamation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate‐to‐brisk erythema, patchy moist desquamation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moist desquamation not limited to creases or skin folds, bleeding subsequent to minor trauma or abrasion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin necrosis or full dermal thickness ulceration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration/fibrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased density on palpation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate functional impairment, not interfering with ADL, increased density and firmness on palpation with or without minor retraction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interferes with ADL, very marked increased density, retraction or fixation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADL: activities of daily living; CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organisation for Research and Treatment of Cancer; RTOG: Radiation Therapy Oncology Group. </p> <p><a href="./references#CD007077-bbs2-0036" title="National Institute of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Effects Version 3.0. ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed 27July 2020).">CTCAE 2006</a>. </p> </div> </div> <div class="table" id="CD007077-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">RTOG/EORTC CTCAE Version 4.0</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade II</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade III</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade IV</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade V</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subcutaneous fibrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild induration, can move skin parallel to the plane (sliding) and perpendicular to the plane (pinching up) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate induration, can slide, cannot pinch up skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe induration cannot slide or pinch skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10 % of body surface area</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 10% of body surface area, psychosocial impact</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate, not limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe, limiting self‐care ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADL: activities of daily living; CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organisation for Research and Treatment of Cancer; RTOG: Radiation Therapy Oncology Group.<br/><a href="./references#CD007077-bbs2-0037" title="National Institute of Health and Human Services, National Cancer Institute. Common Toxicity Criteria for Adverse Effects, Version 4.0. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (accessed 27 July 2020).">CTCAE 2009</a>. </p> </div> </div> <p>Three studies reported radiological or asymptomatic fat necrosis (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>); we were able to report Grade II or greater fat necrosis, as this had the same definition in all three scales (<a href="#CD007077-tbl-0007">Table 6</a>). </p> <div class="table" id="CD007077-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Fat necrosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Grade</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No fat necrosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic fat necrosis (only radiological or cytological findings, or both)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic fat necrosis not requiring medication (palpable mass with or without mild pain) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic fat necrosis requiring medication (palpable mass with significant pain)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic fat necrosis requiring surgical intervention</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD007077-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (BH and ML) assessed trials to check that they met the inclusion criteria and independently assessed methodological quality. Two review authors (BH and ML) independently undertook risk of bias table assessments (EF resolved disagreements) and reported them in the text and as a figure. </p> <p>We described the risk of bias for each included trial. Two review authors (BH and ML) judged risk of bias in eight specific domains, and resolved any differences through discussion. The eight domains were: </p> <p> <ol id="CD007077-list-0007"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessors for objective outcomes;</p> </li> <li> <p>blinding of outcome assessors for subjective outcomes;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other sources of bias (i.e. early stopping and differences in follow‐up examinations).</p> </li> </ol> </p> <p>We will perform sensitivity analyses on the basis of trial quality when additional trials are available. We plan to perform the analysis both with and without trials at low risk of bias to assess the effect of bias on the results when more trials are available to examine. </p> </section> <section id="CD007077-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We presented results as HR for time‐to‐event data and odds ratios (OR) with 95% CI where this was not possible (<a href="./references#CD007077-bbs2-0055" title="HigginsJPT , LiT , DeeksJJ . Choosing effect measures and computing estimates of effect. In: AldersonP , Green S Higgins JP, editors(s). Cochrane Reviewers' Handbook 6.2. Chichester: John Wiley &amp; Sons, 2021.">Higgins 2021</a>). </p> <p>For future updates, if we find results for continuous variables (such as quality of life), we will summarise them using the mean difference (when studies use the same measurement scales) or the standardised mean difference (when studies use different measurement scales) (<a href="./references#CD007077-bbs2-0055" title="HigginsJPT , LiT , DeeksJJ . Choosing effect measures and computing estimates of effect. In: AldersonP , Green S Higgins JP, editors(s). Cochrane Reviewers' Handbook 6.2. Chichester: John Wiley &amp; Sons, 2021.">Higgins 2021</a>). </p> </section> <section id="CD007077-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>Because the unit of analysis was the individual participant, we did not anticipate any unit of analysis issues. Where studies had multiple groups (<a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>), the participants were analysed in the group they were randomised into, so no relevant groups were omitted and double counting was avoided. If cluster RCTs are identified in future updates, we will account for clustering to avoid overestimation of precision which would make CIs too narrow and give the study too much weight. This intervention would not allow crossover studies to be done. </p> </section> <section id="CD007077-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>If data are missing in future updates, we will contact the original investigators (by written correspondence). </p> <p>We will specify what assumptions we make, for example, if we presume the missing data were missing at random, or that missing data were assumed to have a particular value such as a poor outcome. We will, if necessary, perform a sensitivity analysis to see how sensitive results are to the assumptions we have made. We will address the potential implications of this in the 'Discussion' section. </p> </section> <section id="CD007077-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity both visually and statistically using the Chi<sup>2</sup> test of heterogeneity (<a href="./references#CD007077-bbs2-0027" title="AltmanDG . Practical Statistics for Medical Research. London: Chapman and Hall, 1992.">Altman 1992</a>; <a href="./references#CD007077-bbs2-0104" title="WalkerAM , Martin-MorenoJM , ArtalejoFR . Odd man out: a graphical approach to meta-analysis. American Journal of Public Health1988;78(8):961-6.">Walker 1988</a>), and I<sup>2</sup> statistic (<a href="./references#CD007077-bbs2-0053" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>; <a href="./references#CD007077-bbs2-0054" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanGD . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). The criteria for identification of heterogeneity are a P less than 0.10 for the Chi<sup>2</sup> test (acknowledging the limitations of this process) and an I<sup>2</sup> statistic greater than 50%. Where we identified significant heterogeneity, we explored the reasons for it and made a cautious attempt to explain the heterogeneity. </p> </section> <section id="CD007077-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>We acknowledge that there are multiple potential sources of reporting biases, including, but not limited to, publication bias, time‐lag bias, duplicate publication bias and selective outcome reporting. By searching multiple sources including trial registries, we hope to minimise publication bias. We noted the early reporting for the <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> was an example of time‐lag bias. We planned to use funnel plots to evaluate funnel plot asymmetry, but considered that visual interpretation is subjective and that statistical methods to evaluate funnel plot asymmetry are unlikely to be valid if there are fewer than 10 included trials. </p> </section> <section id="CD007077-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We applied the intention‐to‐treat principle in analysing data from the trials and determined a weighted mean treatment effect using the fixed‐effect model to combine results (<a href="./references#CD007077-bbs2-0068" title="MantelN , HaenszelWH . Statistical aspects of the analysis of data for retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719-48.">Mantel 1959</a>) with Review Manager Web (<a href="./references#CD007077-bbs2-0083" title="Review Manager Web (RevMan Web). Version 5.2. The Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web 2019</a>). </p> <p>We used the Mantel‐Haenszel methods to calculate pooled results when there was no significant heterogeneity (<a href="./references#CD007077-bbs2-0049" title="GreenlandS , RobbinsJM . Estimation of a common effect parameter from sparse follow-up data. Biometrics1985;41(1):55-68.">Greenland 1985</a>; <a href="./references#CD007077-bbs2-0068" title="MantelN , HaenszelWH . Statistical aspects of the analysis of data for retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719-48.">Mantel 1959</a>), or if otherwise, the random‐effects model of Der Simonian and Laird (<a href="./references#CD007077-bbs2-0038" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">DerSimonian 1986</a>). </p> </section> <section id="CD007077-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In future updates if data are available, we may perform subgroup analyses to investigate whether the effects of using PBI/APBI or conventional breast RT differ depending on nodal status, margin status, receptor status, hormonal manipulation or tumour stage. </p> <p>If heterogeneity is identified in future updates, we will assess it both statistically and visually using the Chi<sup>2</sup> test of heterogeneity (<a href="./references#CD007077-bbs2-0027" title="AltmanDG . Practical Statistics for Medical Research. London: Chapman and Hall, 1992.">Altman 1992</a>; <a href="./references#CD007077-bbs2-0104" title="WalkerAM , Martin-MorenoJM , ArtalejoFR . Odd man out: a graphical approach to meta-analysis. American Journal of Public Health1988;78(8):961-6.">Walker 1988</a>), and I<sup>2</sup> statistic (<a href="./references#CD007077-bbs2-0053" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>; <a href="./references#CD007077-bbs2-0054" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanGD . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). If we do identify significant heterogeneity, we will explore the reasons for it and attempt to explain it. </p> </section> <section id="CD007077-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform a sensitivity analysis by excluding the trials at high risk of bias for subjective outcomes (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>), but because all studies were at high risk of bias for lack of blinding, this was not done. We performed a sensitivity analysis by excluding the study at high risk of 'other bias' (<a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>); this was a post‐hoc decision. In future updates, if adequate data are available, we will perform a sensitivity analysis to assess the robustness of the results by excluding studies at high risk of bias for subjective outcomes and unpublished trials. </p> </section> <section id="CD007077-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We graded the quality of the evidence and created a summary of findings table using the following outcomes. </p> <p> <ol id="CD007077-list-0008"> <li> <p>LR‐FS.</p> </li> <li> <p>Cosmesis.</p> </li> <li> <p>OS (follow‐up: 5‐year survival).</p> </li> <li> <p>Late toxicity: late subcutaneous breast fibrosis.</p> </li> <li> <p>C‐SS.</p> </li> <li> <p>DM‐FS.</p> </li> <li> <p>Subsequent mastectomy.</p> </li> </ol> </p> <p>The population included women with early breast cancer and the intervention was PBI/APBI versus WBRT. We used <a href="./references#CD007077-bbs2-0048" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), (accessed prior to 26 July 2021). Available at gradepro.org.">GRADEpro GDT</a> and the GRADE approach to evaluate the strength of the evidence (<a href="./references#CD007077-bbs2-0047" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. GRADE Working Group, 2013. Available from gdt.gradepro.org/app/handbook/handbook.html (accessed 4 November 2013).">GRADE 2013</a>). To calculate the absolute risk for the control group for time‐to‐event outcomes, we estimated the event‐free rate at a specific time point (five years for LR‐FS, BC‐SS, DM‐FS, R‐FS and OS) from the Kaplan‐Meier curves or reported event rates. We entered these estimated values in <a href="./references#CD007077-bbs2-0048" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), (accessed prior to 26 July 2021). Available at gradepro.org.">GRADEpro GDT</a>, which automatically calculated the corresponding absolute risks for the intervention group at five years. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007077-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007077-sec-0043"></div> <section id="CD007077-sec-0044"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD007077-sec-0152" title="">Characteristics of included studies</a> table. </p> <section id="CD007077-sec-0045"> <h4 class="title">Results of the search</h4> <p>For this review update, based on our search strategy, we identified and screened 6751 references from the major medical databases and identified 48 additional references from other sources. After exclusion of duplicates and screening of references (by title or abstract), we evaluated 86 full‐text references and excluded one reference (see <a href="./references#CD007077-sec-0153" title="">Characteristics of excluded studies</a> table). Of the remaining 85 references, 19 records related to two new included studies (<a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>), 54 records provided data for seven previously included studies (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>) , 13 records for seven ongoing studies (<a href="./references#CD007077-bbs2-0020" title="NCT00892814. Partial breast versus whole breast irradiation in elderly women operated on for early breast cancer. clinicaltrials.gov/ct2/show/NCT00892814 (first received 5 May 2009). OffersenB , NielsenHM , ThomsenMS , JacobsenEH , NielsenMH , StenbygaardL . Partial breast radiotherapy after breast conservation for breast cancer: early results from the randomised DBCG PBI trial. Radiotherapy and Oncology2017;123(S1):163. ">NCT00892814</a>; <a href="./references#CD007077-bbs2-0021" title="NCT03553797. A phase 3 trial of accelerated whole breast irradiation with hypofractionation plus sequential boost for early stage breast cancer. clinicaltrials.gov/ct2/show/NCT03553797 (first received 6 May 2011). ">NCT03553797</a>; <a href="./references#CD007077-bbs2-0022" title="NCT03583619. A phase II randomized clinical trial of accelerated partial breast irradiation compared with whole breast irradiation with IMRT in early breast cancer. clinicaltrials.gov/ct2/show/NCT03583619 (first received 11 July 2018). ">NCT03583619</a>; <a href="./references#CD007077-bbs2-0023" title="GanzPA , CecchiniRS , WhiteJR , ViciniF , JulianTB , ArthurDW , et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Clinical Oncology2019;37(15 Suppl):508. NCT03616626. Phase III randomized study of adjuvant whole breast versus partial breast irradiation using once daily or twice daily fractionation scheme in women with stage I or II breast cancer. clinicaltrials.gov/ct2/show/NCT03616626 (first received 6 August 2018). ">NCT03616626</a>; <a href="./references#CD007077-bbs2-0024" title="NCT03637738. Medico economic study, comparing Intrabeam® on surgical resection bed to conventional surgery + EBRT, in breast cancer (RIOP-SEIN). clinicaltrials.gov/ct2/show/NCT03637738 (first received 20 August 2018). ">NCT03637738</a>; <a href="./references#CD007077-bbs2-0019" title="MeduriB , BaldisseraA , GaleandroM , DoniniE , TolentoG , GiacobazziP . OC-0568: accelerated PBI vs standard radiotherapy (IRMA trial): interim cosmetic and toxicity results. Radiotherapy and Oncology2017;123(S1):S303. NCT01803958. Breast cancer with low risk of local recurrence: partial and accelerated radiation with three-dimensional conformal radiotherapy (3DCRT) vs. standard radiotherapy after conserving surgery (phase III study). clinicaltrials.gov/ct2/show/NCT01803958 (first received 4 March 2013). ">IRMA</a>; <a href="./references#CD007077-bbs2-0025" title="BelkacemiY , BourgierC , KramarA , AuzacG , DumasI , LacornerieT , et al. SHARE: a French multicenter phase III trial comparing accelerated partial irradiation versus standard or hypofractionated whole breast irradiation in breast cancer patients at low risk of local recurrence. Clinical Advances in Haematology and Oncology2013;11(2):76-83. BelkacemiY , BourgierC , KramarA , LemonierJ , AuzacG , DumasI . SHARE. A French multicenter phase III trial comparing accelerated partial irradiation (APBI) versus standard or hypofractionated whole breast irradiation in low risk of local recurrence breast cancer. Cancer Research2012;72:24S. NCT01247233. Standard or hypofractionated radiotherapy versus accelerated partial breast irradiation (PBI/APBI) for breast cancer (SHARE). clinicaltrials.gov/ct2/show/NCT01247233 (first received 24 November 2010). [ISRCTN62704822]">SHARE</a>), and three records for two studies awaiting classification (<a href="./references#CD007077-bbs2-0017" title="NCT02375048. Randomized study on postmenopausal women with early stage breast cancer: WBI versus APBI. clinicaltrials.gov/ct2/show/NCT02375048 (first received 2 March 2015). RoseD , FranceschiniD , IftodeC , ComitoT , TozziA , FranzeseC , et al. Randomized phase II study of hypofractionated WBI versus APBI using VMAT: early toxicity results. Radiotherapy and Oncology2018;127(S1):S700. ">NCT02375048</a>; <a href="./references#CD007077-bbs2-0018" title="YadavBS , LoganathanS , SharmaSC , SinghR , DahiyaD . Comparison of toxicity and cosmetic outcomes after accelerated partial breast irradiation or whole breast irradiation using 3-dimensional conformal external beam radiation therapy. Advances in Radiation Oncology2020;5(2):171-9. YadavBS , SharmaSC , SinghR , DahiyaD . Comparison of accelerated partial breast irradiation (APBI) with whole breast irradiation (WBI) using 3D conformal external beam radiation therapy (3D CRT). Cancer Research2019;79(4 Suppl):P3-12-13. ">Yadav 2019</a>). See <a href="#CD007077-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD007077-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD007077-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>Overall, when combining the original (<a href="./references#CD007077-bbs2-0112" title="HickeyBE , LehmanM , FrancisDP , SeeAM . Partial breast irradiation for early breast cancer. Cochrane Database of Systematic Reviews2016, Issue 7. Art. No: CD007077. [DOI: 10.1002/14651858.CD007077.pub3]">Hickey 2016</a>) and review update, there were nine included studies, seven excluded studies, two studies await classification and seven ongoing studies. In summary, this review update included nine studies and the qualitative analysis included nine studies (<a href="#CD007077-fig-0001">Figure 1</a>). </p> </section> <section id="CD007077-sec-0046"> <h4 class="title">Included studies</h4> <section id="CD007077-sec-0047"> <h5 class="title">Design</h5> <p>Nine RCTs enrolled 15,187 women (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>); we studied 14,245 women included in these studies. These studies enrolled women from July 1998 to May 2004 (<a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>), February 2006 to July 2011 (<a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>), November 2000 to December 2007 (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>), March 2000 to June 2011 (<a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>), March 2005 to June 2013 (<a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>), April 2004 to July 2009 (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>), March 2005 to April 2016 (<a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>), and 2007 to 2010 (<a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>). <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> did not state accrual dates. </p> </section> <section id="CD007077-sec-0048"> <h5 class="title">Sample size</h5> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> enrolled 258 women of a planned sample size of 570 participants, <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> enrolled 2135 women, <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> enrolled 102 women, <a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> enrolled 1305 women, <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> enrolled 2298 women, <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> enrolled 520 women, <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> enrolled 2016 women, and <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> enrolled 1184 women, and <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a> enrolled 4216 women. </p> </section> <section id="CD007077-sec-0049"> <h5 class="title">Setting</h5> <p>Four studies were single institution trials from tertiary institutions: one in Hungary (<a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>), two in Italy (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>), and one in Spain (<a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>). <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>, <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>, <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>, and <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> were multicentred, international studies. <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> was a multicentre study from the UK. </p> </section> <section id="CD007077-sec-0050"> <h5 class="title">Participants</h5> <p>A total of 15,187 women with invasive breast cancer or ductal carcinoma in situ (DCIS (6.3%) with T1‐2N0‐1M0 Grade I or II unifocal tumours (less than 2cm or 3 cm or less) treated with breast‐conserving surgery who had negative margins (see <a href="./references#CD007077-sec-0152" title="">Characteristics of included studies</a> table and <a href="#CD007077-tbl-0008">Table 7</a>). </p> <div class="table" id="CD007077-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Participants</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Stage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Margins</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tumour size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nodal status</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 2000, &lt; 40 years excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unifocal tumour, pT1N0‐1miM0, Grade I or II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2.0 cm</p> <p>(&lt; 2 mm: 1/258, ≥ 2 mm: 246/258 or had no tumour at ink: 11/258)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48–75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Early breast cancer," "suitable for breast conservation"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 2.5 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD if SNBx positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 40 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative, ≥ 5 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 2.5 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLE or quadrantectomy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1 and small T2N0‐1M0 invasive breast cancer, suitable for BCS, available for 10 years' follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1 mm</p> <p>Re‐excision strongly advised for close or positive margins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 40 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DCIS<sup>a</sup> or invasive breast cancer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative axillary nodal involvement including micrometastasis (&gt; 0.2 mm or positive cells only identified on IHC as determined by sentinel node biopsy; axillary node dissection or clinical examination for DCIS only. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive ductal carcinoma <i>(</i>pT1‐2cNO MO), unifocal tumour, Grade I or II </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 3 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive breast cancer pT1‐2pN0 who have &lt; 1% annual risk of local recurrence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0–3 nodes positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 40 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 0, I or II pN0/pNmi breast cancer (including DCIS) no vascular invasion, unifocal or unicentric disease only, no LVINote: 60/1184 (5%) participants had DCIS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 mm in invasive disease, 5 mm in DCIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lesions &lt; 3 cm in diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Node negative, for DCIS alone: sentinel node biopsy optional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLE or quadrantectomy, level I–II axillary dissection, removing ≥ 6 (preferably 10 lymph nodes) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T0‐2N0‐1M0 DCIS or invasive breast cancer</p> <p>Note: 531/4216 (12%) participants had DCIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative: "free of cancer, including DCSI"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lesions &lt; 3 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 involved nodes permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lumpectomy</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AD: axillary dissection; BCS: breast‐conserving surgery; DCIS: ductal carcinoma in situ; IHC: immunohistochemistry; LVI: lymphovascular invasion; SNBx: sentinel node biopsy; WLE: wide local excision.<br/><sup>a</sup>366/2135 participants had DCIS. </p> </div> </div> </section> <section id="CD007077-sec-0051"> <h5 class="title">Interventions</h5> <section id="CD007077-sec-0052"> <h6 class="title">Experimental arms</h6> <p>PBI using:</p> <p> <ol id="CD007077-list-0009"> <li> <p>APBI (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>), conventional fractionation (<a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>), or hypofractionation (<a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>); </p> </li> <li> <p>brachytherapy:</p> <ol id="CD007077-list-0010"> <li> <p>high‐dose rate (HDR) brachytherapy;</p> </li> <li> <p>pulsed‐dose rate (PDR) brachytherapy;</p> </li> </ol> </li> <li> <p>EBRT delivered:</p> <ol id="CD007077-list-0011"> <li> <p>via conventionally fractionated (2 Gy per fraction) (<a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>); </p> </li> <li> <p>at greater than 2 Gy per fraction delivered via 3D‐CRT or IMRT using a linear accelerator (<a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>); </p> </li> <li> <p>using electrons;</p> </li> <li> <p>using kilovoltage EBRT (see <a href="#CD007077-tbl-0009">Table 8</a> for details). </p> </li> </ol> </li> </ol> </p> <div class="table" id="CD007077-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>RT quality assurance</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>RT technique</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>PIB/APBI target volume definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postimplant CT scans were performed<br/>for 17/87 (20%) participants to document PTV coverage </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interstitial brachytherapy (88/128)</p> <p>EBRT using photons (40/128)</p> <p>2‐dimensional CT‐based<br/>treatment planning was used for all participants </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTV: excision cavity delineated by the surgical clips + 2 cm isotropic margin. For interstitial therapy: if electrons were used, 6–15 MeV were used to treat the cavity with a 2 cm margin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intraoperative electrons 6–9 MeV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV: quote: "decided according to the site and size of the tumour. The energy of the electron beams was selected according to the thickness of the gland measured by a graduated needle" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EBRT (IMRT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV = +1 cm isotropic margin around surgical clips</p> <p>PTV = CTV +10 mm isotropic margin<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intraoperative kV RT</p> <p>3D‐CRT for WBRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The target volume was the tumour cavity<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EBRT (3D‐CRT)</p> <p>APBI: 3–5 non‐coplanar fields</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV = tumour bed on CT (surgical clips plus a 1‐cm margin inside breast<br/>tissue) </p> <p>PTV = CTV +1 cm isotropic margin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EBRT (3D‐CRT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTV was defined by contouring the same quadrant as the primary tumor site<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Field‐in‐field IMRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumour bed, surgical clips<sup>g</sup> recommended </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDR or PDR multicatheter brachytherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBI: tumour bed<sup>i</sup> +2 cm isotropic margin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Every institution's RT facilities were quality assessed and each case of APBI was centrally reviewed for RT quality." Benchmarking performed with "dummy run" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDR brachytherapy<sup>j</sup> </p> <p>APBI EBRT: 3D‐CRT<sup>k</sup> (IMRT not permitted). </p> <p>WBRT: 3D‐CRT (IMRT not permitted)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No RNI permitted</p> <p>WBRT: entire ipsilateral breast</p> <p>APBI: CTV = cavity = PTV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RT quality assurance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RT technique</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Target volume definition</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>3D‐CRT: 3‐dimensional conformal radiotherapy; APBI: accelerated partial breast irradiation; CRT: conformal radiotherapy; CT: computer tomography; CTV: clinical target volume; EBRT: external beam radiotherapy; HDR: high‐dose rate; IMRT: intensity‐modulated radiotherapy; PDR: pulsed‐dose rate; PIB: partial breast irradiation; PTV: planning target volume; RNI: regional nodal irradiation; RT: radiotherapy; WBRT: whole breast radiotherapy. </p> <p><sup>a</sup>The surgeons were requested to place clips at the borders of the surgical bed, using a minimum of four clips. CTV was drawn on a planning CT (0.3 mm slices) with a uniform 1 cm margin around the surgical clips, then a 1 cm margin added to construct the PTV.<br/><sup>b</sup>For the WBRT component of <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>, as long as treating centres conformed to a formal quality management system issued by the International Standards Organisation, no additional quality assurance was required. For the APBI, quality assurance was performed according to the manufacturer's instructions and the resulting data to be made available to the trials centre. Data were submitted either annually or after every 50th participant treated with Intrabeam.<br/><sup>c</sup>Quote: "The appropriately sized (1.5–5.0 cm diameter) applicator is placed in the tumour bed using a meticulous surgical technique, including a carefully inserted purse‐string suture that ensures that breast tissues at risk of local recurrence receive the prescribed dose while skin and deeper structures are protected. Radiation is delivered over 20–45 min to the tumour bed. The surface of the tumour bed typically receives 20 Gy that attenuates to 5–7 Gy at 1 cm depth."<br/><sup>d</sup>Before study opening, physicians' tumour bed contouring and centres' APBI planning were credentialed. Centres completed real‐time review of at least 10 APBI patient cases before treatment and final review of all patient cases.<br/><sup>e</sup>To avoid interobserver variability, this was performed by the same radiation oncologist. Surgical clips were not available at the institution at the time.<br/><sup>f</sup>Baseline questionnaire completed by centre, UK Radiotherapy Trial Quality Assurance (RTQA) validated the treatment technique, a phantom was used, all plans and data sets collected and stored at RTQA, every 10th enrolled participant was selected at random to have thermo‐luminescent dosimetry measurements, which were sent to RTQA.<br/><sup>g</sup>If no clips had been inserted, ultrasound, magnetic resonance imaging or CT was used. If no localisation procedure had been done, study entry was permitted if the clinician was confident that clinical localisation was accurate.<br/><sup>h</sup>Both pre‐ and postimplant assessment of geometry using CT, dose prescription and calculations were in accordance with International Commission of Radiation Units and Measurements (ICRU) 58 and strict dose volume histogram and dose maximums were mandated, the post‐hoc quality assurance requirements were clearly detailed in the study protocol (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>).<br/><sup>i</sup>Tumour bed localised using clips, preoperative mammographic and ultrasound imaging and planning scan.<br/><sup>j</sup>HDR multicatheter, HDR single entry (MammoSite single‐lumen, MammoSite multi‐lumen, Contura multi‐lumen balloon).<br/><sup>k</sup>10 fractions, given with six‐hour gap on five treatment days within an eight‐day period. </p> </div> </div> </section> <section id="CD007077-sec-0053"> <h6 class="title">Control arm</h6> <p>WBRT using conventional fractionation: dose ranged from 42.5 Gy to 56 Gy, the use of a boost was variable (see <a href="#CD007077-tbl-0009">Table 8</a> for details). </p> </section> <section id="CD007077-sec-0054"> <h6 class="title">Co‐interventions</h6> <p>Chemotherapy and hormonal manipulation: in <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>, <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>, <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>, <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>, <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>, and <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>, women received adjuvant systemic therapy according to institutional protocol, and <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> treated oestrogen receptor‐positive women with hormonal manipulation. Systemic therapy in <a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> was "administered according to the European Institute of Oncology policy" at the time (see <a href="./references#CD007077-sec-0152" title="">Characteristics of included studies</a> table for further details). In total, 6372/6820 (93%) women received hormonal manipulation and 977/6820 (14.3%) women received chemotherapy. </p> <p><a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> treated women with four or more involved nodes with regional nodal RT. No women in any of the other included studies received regional nodal RT (<a href="#CD007077-tbl-0009">Table 8</a>). </p> </section> </section> <section id="CD007077-sec-0055"> <h5 class="title">Outcomes</h5> <section id="CD007077-sec-0056"> <h6 class="title">1.0 Primary outcomes</h6> <section id="CD007077-sec-0057"> <p><b>1.1 Local recurrence‐free survival</b></p> <p>Nine studies reported local recurrence in the ipsilateral breast as a discrete outcome (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>;<a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>), but because in <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> there were zero events on both study arms, it was not included in the analysis. </p> </section> <section id="CD007077-sec-0058"> <p><b>1.2 Cosmesis</b></p> <p>Six studies reported cosmesis (cosmetic outcome). <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>, <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>, and <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> reported a global cosmetic result (used the Harvard Cosmetic Score (see <a href="#CD007077-tbl-0002">Table 1</a>)). <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> and <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> used the EORTC Cosmetic Rating System for Breast Cancer (<a href="./references#CD007077-bbs2-0026" title="AaronsonNK , BartelinkH , vanDongenJA , vanDamFS . Evaluation of breast conserving therapy: clinical, methodological and psychological perspectives. European Journal of Surgery1998;14:133-40.">Aaronson 1998</a>); both were four‐point scales. <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> evaluated cosmesis using digital photos, with both participant‐reported outcomes and physician‐reported outcomes using a four‐point scale (<a href="./references#CD007077-bbs2-0106" title="WazerDE , DiPetrilloT , Schmidt-UllrichR , WeldL , SmithTJ , MarchantDJ , et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. Journal of Clinical Oncology1992;10:356-63.">Wazer 1992</a>; see <a href="#CD007077-tbl-0010">Table 9</a>). <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>, <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>, and <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> included participant‐reported outcomes. Trained nurses also assessed cosmetic outcomes in <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>. Assessment of cosmetic outcome was blinded in <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>. <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> assessed cosmetic outcome at a single centre in a substudy that included 105 women. A software program, blinded to treatment arm, assessed digital photos at a median 23 months using a four‐point scale. </p> <div class="table" id="CD007077-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Brachytherapy cosmetic score</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Score</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perfect symmetry, no visible distortion or skin changes and no visible catheter entry/exit sequelae </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slight skin distortion, retraction or oedema, any visible telangiectasia, any visible catheter entry/exit scar or mild hyperpigmentation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate distortion of the nipple or breast symmetry, moderate hyperpigmentation, or prominent skin retraction, oedema or telangiectasia </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marked distortion, oedema, fibrosis or severe hyperpigmentation</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD007077-sec-0059"> <h6 class="title">2.0 Secondary outcomes</h6> <section id="CD007077-sec-0060"> <p><b>2.1 Overall survival</b></p> <p>Nine studies reported OS (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>;<a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> ; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>) but because in <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> there were zero events on both study arms, it was not included in the analysis. </p> </section> <section id="CD007077-sec-0061"> <p><b>2.2 Toxicity</b></p> <p>Five studies reported acute skin toxicity. <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>, <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>, and <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> used the Radiation Therapy Oncology Group Common Toxicity Criteria (RTOG CTC) (<a href="./references#CD007077-bbs2-0035" title="CoxJD , StetzJ , PajakTH . Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer. International Journal of Radiation Therapy Oncology, Biology, Physics1995;31:1341-6.">Cox 1995</a>; <a href="#CD007077-tbl-0003">Table 2</a>), <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> used CTCAE Version 4.0 (<a href="./references#CD007077-bbs2-0037" title="National Institute of Health and Human Services, National Cancer Institute. Common Toxicity Criteria for Adverse Effects, Version 4.0. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (accessed 27 July 2020).">CTCAE 2009</a>) and <a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> used a five‐point scale (which was not referenced). </p> <p>Six studies reported late toxicity (telangiectasia (small blood vessels visible on the treated skin), breast pain, fat necrosis and subcutaneous fibrosis). <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> reported fat necrosis at four years according to a five‐point institutional scale (<a href="#CD007077-tbl-0007">Table 6</a>); <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> reported late RT toxicity (telangiectasia, induration (subcutaneous fibrosis), breast pain and fat necrosis) using the National Cancer Institute Common Toxicity Criteria (NCI CTC 3.0; <a href="./references#CD007077-bbs2-0072" title="Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (accessed 29 July 2015).">NCI</a>; three‐point scales; <a href="#CD007077-tbl-0004">Table 3</a>). <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> reported late toxicity (breast pain, late subcutaneous toxicity and late RT skin toxicity) using the RTOG/EORTC CTC (<a href="./references#CD007077-bbs2-0035" title="CoxJD , StetzJ , PajakTH . Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer. International Journal of Radiation Therapy Oncology, Biology, Physics1995;31:1341-6.">Cox 1995</a>). <a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> reported fat necrosis and radiological radiation pneumonitis using late effects of normal tissue – subjective objective management analytic criteria (LENT‐SOMA; <a href="./references#CD007077-bbs2-0076" title="PavyJJ , DenekampJ , LetshcertJ , LittbrandB , MornexF , BernierJ , et al. Later Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiotherapy and Oncology1995;35:11-3.">Pavy 1995</a>). <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> scored late RT toxicity using the RTOG/EORTC CTC (<a href="./references#CD007077-bbs2-0035" title="CoxJD , StetzJ , PajakTH . Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer. International Journal of Radiation Therapy Oncology, Biology, Physics1995;31:1341-6.">Cox 1995</a>). <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> reported "complications arising six months after randomisation" and reported RTOG/EORTC CTC (<a href="./references#CD007077-bbs2-0035" title="CoxJD , StetzJ , PajakTH . Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer. International Journal of Radiation Therapy Oncology, Biology, Physics1995;31:1341-6.">Cox 1995</a>) Grade III or IV RT‐related skin complications, haematomas/seromas requiring greater than three aspirations or surgery, wound infections requiring intravenous antibiotics or surgery, and skin breakdown/delayed wound healing. </p> </section> <section id="CD007077-sec-0062"> <p><b>2.3 New primary tumours in ipsilateral breast ('elsewhere primaries')</b></p> <p>Four studies reported new primary tumours in ipsilateral breast (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>). </p> </section> <section id="CD007077-sec-0063"> <p><b>2.4 Cause‐specific survival</b></p> <p>Seven studies reported C‐SS (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>). </p> </section> <section id="CD007077-sec-0064"> <p><b>2.5 Distant metastasis‐free survival</b></p> <p>Eight studies reported DM‐FS (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>) but because in <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> there were zero events on both study arms, it was not included in the analysis. </p> </section> <section id="CD007077-sec-0065"> <p><b>2.6 Relapse‐free survival</b></p> <p>Six studies reported R‐FS: <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>;<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>). The data reported in <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> were not in a usable form. </p> </section> <section id="CD007077-sec-0066"> <p><b>2.7 Locoregional recurrence‐free survival</b></p> <p>Six studies reported L‐RR‐FS (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>), but because in <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> there were zero events on both study arms, it was not included in the analysis. </p> </section> <section id="CD007077-sec-0067"> <p><b>2.8 Subsequent mastectomy</b></p> <p>Three studies reported subsequent mastectomy (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). </p> </section> <section id="CD007077-sec-0068"> <p><b>2.9 Compliance</b></p> <p>All nine studies reported compliance (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). </p> </section> <section id="CD007077-sec-0069"> <p><b>2.10 Costs</b></p> <p>We found no trials reporting costs.</p> </section> <section id="CD007077-sec-0070"> <p><b>2.11 Quality of life</b></p> <p>Three studies reported quality of life. <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> used the Breast Cancer Questionnaire (a validated modification of the Breast Cancer Chemotherapy Quality of Life Questionnaire; <a href="./references#CD007077-bbs2-0065" title="LevineMN , GuyattGH , GentM , De PauwS , GoodyearMD , HryniukWM , et al. Quality of life in stage II breast cancer an instrument for clinical trials. Journal of Clinical Oncology1998;6:1798-810.">Levine 1998</a>) and <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> and <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> used the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30; <a href="./references#CD007077-bbs2-0026" title="AaronsonNK , BartelinkH , vanDongenJA , vanDamFS . Evaluation of breast conserving therapy: clinical, methodological and psychological perspectives. European Journal of Surgery1998;14:133-40.">Aaronson 1998</a>) and Quality of Life Questionnaire – Breast Specific Module (QLQ‐BR23) (<a href="./references#CD007077-bbs2-0090" title="SprangersMA , GroenvoldM , ArrarasJL , Franklin J te VeldeA , MullerM , et al. The European Organisation for Research and Treatment of Cancer cancer-specific quality-of-life questionnaire module: first results from a three-country field study. Journal of Clinical Oncology1996;14:2756-68.">Sprangers 1996</a>). </p> </section> <section id="CD007077-sec-0071"> <p><b>2.12 Consumer preference</b></p> <p>We found no trials reporting consumer preference.</p> <p>The included RCTs differed in several ways.</p> <p> <ol id="CD007077-list-0012"> <li> <p>Population included.</p> </li> <li> <p>Margin size.</p> </li> <li> <p>Target volume definition for the treated PBI/APBI volume varied between the trials.</p> </li> <li> <p>Radiation dose prescribed differed greatly between the trials (see <a href="#CD007077-tbl-0011">Table 10</a>). </p> </li> <li> <p>RT technique for PBI/APBI delivery differed.</p> </li> <li> <p>RT fractionation varied across studies.</p> </li> <li> <p>Quality assurance of RT.</p> </li> <li> <p>One study did not accrue the full sample size: <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> stopped early because a competing multicentred RCT was started (for details see <a href="#CD007077-tbl-0008">Table 7</a>, <a href="#CD007077-tbl-0009">Table 8</a>, <a href="#CD007077-tbl-0012">Table 11</a>). </p> </li> </ol> </p> <div class="table" id="CD007077-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Radiotherapy doses prescribed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>PBI/APBI dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Fraction size (Gy)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>EQD<sub>2</sub> PBI/APBI</b> </p> <p><b>alpha/beta = 4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Control dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Fraction size (Gy)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>EQD<sub>2</sub> Control</b> </p> <p><b>alpha/beta = 4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 Gy at surface of the applicator (attenuated to 5–7 Gy at 1 cm) (APBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 at cavity surface</p> <p>12.8 at 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 Gy at cavity</p> <p>surface</p> <p>12.8 Gy at 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40–56 Gy/20–28 fractions ± 10–16 Gy boost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40–56 Gy ±</p> <p>10–16 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 Gy/5 daily fractions EBRT IMRT. 100% of the PTV was covered by 95% of the prescribed dose </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy/25 fractions + 10 Gy/5 fractions boost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 + 10 = 60 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5 Gy/10 fractions twice daily (with 6‐hour gap)</p> <p>Dose‐evaluation volume (that part of PTV within the breast) received 95–107% of prescription dose </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.4 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy/25 fractions or 42.5 Gy/16 fractions ± boost (10 Gy/4–5 fractions) based on criteria such as young age or close margins, prespecified by centre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 or 2.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy or 47.1 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5 Gy/10 fractions twice daily (with 6‐hour gap) (APBI). PTV covered by ≥ 95% of prescribed dose, with &lt; 105% hot spot </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.48 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 Gy/24 fractions ± 10 Gy/5 fractions boost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 ± 10 = 48–58 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 × 5.2 Gy HDR (APBI) or 50 Gy/25 fractions (PBI)<br/>Women unsuitable for HDR had 6–15 MeV beam to tumour bed plus 2 cm margin (field size defined using CT‐planning or simulation films) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 or 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.5 Gy or 50 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy/25 fractions (3D‐CRT was not used)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.3 Gy/7 fractions or 32 Gy/8 fractions HDR twice daily or 50 Gy at 0.6–0.8 Gy/hour pulses (1 pulse per hour, 24 hours per day) PDR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7–8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.64–42.67 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0–50.4 Gy to a reference point + 10 Gy/5 fractions boost. Electron dose was prescribed to the point of maximum dose on the beam axis (D<sub>max</sub>), ensuring the 85% isodose encompassed the tumour bed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8–2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.72–50 + 10 = 58.72–60 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 Gy/1 fraction at 90% using 6–9 MeV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy/25 fractions + 10 Gy/5 fractions boost (using electrons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 + 10 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 Gy/15 fractions (EBRT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 Gy/15 fractions</p> <p>36 Gy/15 fractions + boost 40 Gy/15 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.72</p> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.23</p> <p>38.4 + 45.23</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>3D‐CRT: 3‐dimensional conformal radiotherapy; APBI: accelerated partial breast irradiation; CT: computer tomography; EBRT: external beam radiotherapy; EQD<sub>2</sub>: equivalent dose in 2 Gy fractions; Gy: Gray; HDR: high‐dose‐rate; IMRT: intensity‐modulated radiotherapy; MeV: mega electron volt; PBI: partial breast irradiation; PDR: pulsed‐dose rate; PTV: planning target volume. </p> </div> </div> <div class="table" id="CD007077-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Stud</b>y </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mammography</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Radiotherapy toxicity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Patient‐reported outcomes (PRO)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cosmesis</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6 months, then annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute: CTCAE<sup>a</sup> </p> <p>Late: EORTC/RTOG<sup>b</sup> and LENT‐SOMA<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Harvard Cosmetic Score<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LENT‐SOMA<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute and late: EORTC/RTOG<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC QLQ‐C30<sup>e</sup> </p> <p>QLQ‐BR23 breast cancer module<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Harvard Cosmetic Score<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute: nil</p> <p>Late: EORTC/RTOG,<sup>b</sup> LENT‐SOMA,<sup>c</sup> CTCAE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC QLQ‐C30<sup>e</sup> </p> <p>QLQ‐BR23 breast cancer module</p> <p>Body‐image scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinician and nurse assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute and late: NCI version 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC QLQ‐C30<sup>e</sup> </p> <p>QLQ‐BR23 breast cancer module</p> <p>Body‐image scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC/RTOG Rating System<sup>g</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline 6 months after RT than annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late: EORTC/RTOG<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Harvard Cosmetic Score<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually 1–5 years,</p> <p>3 yearly to 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic rib fracture</p> <p>and lung fibrosis</p> <p>Ischaemic heart disease</p> <p>recorded at 1, 2, 5 and</p> <p>10 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC QLQ‐C30<sup>e</sup> </p> <p>QLQ‐BR23 breast cancer module</p> <p>Body‐image scale</p> <p>protocol‐specific questions<sup>h</sup> </p> <p>HADS scale</p> <p>EuroQol EQ‐5D‐3L health status questionnaire</p> <p>at baseline; 6 months; 1, 2 and 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐ and</p> <p>clinician‐assessed<sup>i</sup> </p> <p>Photos<sup>j</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6, 12, 18, 24 months after radiotherapy then annually for 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fat necrosis measured using Lövey scoring system<sup>k</sup> </p> <p>Physician scored late toxicity</p> <p>Acute radiotherapy toxicity: CTCAE version 3.0<sup>a</sup> </p> <p>LENT‐SOMA<sup>c</sup> </p> <p>Late RT toxicity: EORTC/RTOG<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breast pain and arm lymphoedema measured by CTCAE version 3.0<sup>a</sup> </p> <p>EORTC QLQ‐C30<sup>e</sup> and QLQ‐BR23 at baseline and during follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Harvard Cosmetic Score<sup>d</sup> </p> <p>Physician‐ and patient‐reported</p> <p>Digital photos<sup>l</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute radiotherapy toxicity: CTCAE version 4.0</p> <p>Late RT toxicity: CTCAE version 4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physician reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organisation for Research and Treatment of Cancer; EORTC QLQ‐C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; EORTC QLQ‐BR23: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Breast Specific Module; EORTC/RTOG: European Organisation for Research and Treatment of Cancer/Radiation Therapy Oncology Group; HADS: Hospital Anxiety and Depression Scale; LENT‐SOMA: late effects in normal tissues – subjective objective, management and analytic; RT: radiotherapy. </p> <p><sup>a</sup><a href="./references#CD007077-bbs2-0096" title="TrottiA , ColevasAE , SetserA , RuschV , JaquesD , BudachV , et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology2003;13:176-81.">Trotti 2013</a>.<br/><sup>b</sup><a href="./references#CD007077-bbs2-0084" title="Anon. Late effects consensus conference: RTOG/EORTC. Radiotherapy and Oncology1995;35:5-7.">Rubin 1995</a>.<br/><sup>c</sup><a href="./references#CD007077-bbs2-0029" title="Anonymous. LENT SOMA tables. Radiotherapy and Oncology1995;35:17-60.">Anon 1995</a>.<br/><sup>d</sup>Harvard Cosmetic Score uses a four‐point scale: excellent, good, fair or poor (<a href="./references#CD007077-bbs2-0050" title="HarrisJ , LevineM , SvensonG , HellmanS . Analysis of cosmetic results following primary radiation therapy for Stage I and II carcinoma of the breast. International Journal of Radiation Oncology Biology, Physics1979;5:257-61.">Harris 1979</a>).<br/><sup>e</sup>The EORTC QLQ‐C30 includes nine multi‐item scales: five functional (physical, role, emotional, cognitive and social), three symptom scales (fatigue, pain and nausea‐vomiting) and a global health status (GHS) health‐related quality of life scale. There are six single‐item symptom measures: insomnia, appetite loss, constipation, diarrhoea and financial difficulties). The symptom measures are scored on a four‐point scale, with high scores representing a higher symptom burden. The GHS scale is scored using a visual analogue scale: one (very bad) to seven (excellent), so a higher score on GHS or the functional scale is good (<a href="./references#CD007077-bbs2-0026" title="AaronsonNK , BartelinkH , vanDongenJA , vanDamFS . Evaluation of breast conserving therapy: clinical, methodological and psychological perspectives. European Journal of Surgery1998;14:133-40.">Aaronson 1998</a>).<br/><sup>f</sup>The BR23 module uses 23 questions to assess symptoms, treatment adverse effects, body image, sexual function and future perspective using five multi‐item scales. The symptom measures are scored on a four‐point scale, so high scores represent a higher symptom burden. The other aspects are scored so a higher score is better (<a href="./references#CD007077-bbs2-0090" title="SprangersMA , GroenvoldM , ArrarasJL , Franklin J te VeldeA , MullerM , et al. The European Organisation for Research and Treatment of Cancer cancer-specific quality-of-life questionnaire module: first results from a three-country field study. Journal of Clinical Oncology1996;14:2756-68.">Sprangers 1996</a>).<br/><sup>g</sup>The EORTC/RTOG Rating System is a four‐point scale, assessed by trained nurses, physicians and participant‐reported outcomes (<a href="./references#CD007077-bbs2-0026" title="AaronsonNK , BartelinkH , vanDongenJA , vanDamFS . Evaluation of breast conserving therapy: clinical, methodological and psychological perspectives. European Journal of Surgery1998;14:133-40.">Aaronson 1998</a>).<br/><sup>h</sup>Has skin appearance changed, overall breast appearance changed, breast become smaller, breast become harder or firmer to touch, is shoulder stiffness present?<br/><sup>i</sup>Breast shrinkage, distortion, induration, breast oedema, telangiectasia assessed using four‐point scale (not at all, a little, quite a bit and very much). Photos taken at baseline and 2 and 5 years.<br/><sup>j</sup>Photos scored as showing no change, mild or marked change in breast appearance at 2 and 5 years compared with baseline by three observers masked to treatment allocation using a validated consensus method (<a href="./references#CD007077-bbs2-0051" title="HavilandJS , AshtonA , BroadB , GothardL , OwenJR , TaitD , et al. Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer. Clinical Oncology2008;20:497-501.">Haviland 2008</a>).<br/><sup>k</sup><a href="./references#CD007077-bbs2-0066" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4-year results of a randomized trial. International Journal of Radiation Oncology Biology, Physics2007;69:724-31.">Lövey 2007</a>.<br/><sup>l</sup>Digital photos assessed using a validated consensus method by three observers masked to treatment allocation. </p> </div> </div> </section> </section> </section> </section> <section id="CD007077-sec-0072"> <h4 class="title">Excluded studies</h4> <p>We excluded seven studies. Two studies did not use contemporary surgical or RT techniques, one study was not an RCT, three studies used PBI in both study arms and one study used WBRT in both study arms (for details, see <a href="./references#CD007077-sec-0153" title="">Characteristics of excluded studies</a> table). </p> </section> </section> <section id="CD007077-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD007077-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD007077-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007077-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007077-sec-0074"> <h4 class="title">Allocation</h4> <p>All studies were at low risk of bias for random sequence generation. Three were at unclear risk of allocation concealment (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>), and the remaining six studies were at low risk of bias for allocation concealment (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). </p> </section> <section id="CD007077-sec-0075"> <h4 class="title">Blinding</h4> <section id="CD007077-sec-0076"> <h5 class="title">Objective outcomes</h5> <p>All studies were at low risk of performance bias for lack of blinding for objective outcomes. All studies were at low risk of detection bias for objective outcomes. </p> </section> <section id="CD007077-sec-0077"> <h5 class="title">Subjective outcomes</h5> <p>Seven studies were at high risk of performance bias for lack of blinding for subjective outcomes (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>), one study was at unclear risk of bias (<a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>), and one study was at low risk of bias for this domain (<a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>). One study was at low risk of detection bias for subjective outcomes (<a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>), and eight studies were at high risk of bias (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). </p> </section> </section> <section id="CD007077-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>Nine studies were at low risk of attrition bias.</p> </section> <section id="CD007077-sec-0079"> <h4 class="title">Selective reporting</h4> <p>Three studies were at low risk of reporting bias (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>), while the remaining studies were at unclear risk. </p> </section> <section id="CD007077-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> had low risk of bias as they stopped the trial early because a competing trial started recruiting (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>). We identified no other sources of bias for <a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>, <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>, <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>, <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>, and <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> so deemed them at low risk of bias. <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> was an interim report and, therefore, at unclear risk of other bias. </p> <section id="CD007077-sec-0081"> <h5 class="title">Risk of bias by outcome</h5> <section id="CD007077-sec-0082"> <h6 class="title">1.1 Local recurrence‐free survival</h6> <p>Seven of eight studies contributing data to this outcome were at low risk of bias. One study was at high risk of bias for inadequate follow‐up duration to detect the outcome (<a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). </p> </section> <section id="CD007077-sec-0083"> <h6 class="title">1.2 Cosmesis</h6> <p>One of six studies contributing data with respect to physician or nurse‐evaluated cosmesis was at low risk of bias, and four of six at high risk of bias for lack of blinding for outcome assessors. </p> </section> <section id="CD007077-sec-0084"> <h6 class="title">2.1 Overall survival</h6> <p>All eight studies contributing data to this outcome were at low risk of bias for sequence generation; four of eight studies were at unclear risk of bias for allocation concealment. </p> </section> <section id="CD007077-sec-0085"> <h6 class="title">2.2 Toxicity</h6> <section id="CD007077-sec-0086"> <p><b>2.2.1 Acute radiotherapy toxicity</b></p> <p>All studies contributing data to this outcome were at high risk of bias for lack of blinding for outcome assessors. </p> </section> <section id="CD007077-sec-0087"> <p><b>2.2.2 Late radiotherapy toxicity</b></p> <p>All studies contributing data to this outcome were at high risk of bias for lack of blinding for outcome assessors, with the exception of radiological fat necrosis, where two of two studies were at low risk of bias. </p> </section> </section> <section id="CD007077-sec-0088"> <h6 class="title">2.3 New primary tumours in ipsilateral breast 'elsewhere primary'</h6> <p>Three of four studies contributing data to this outcome were at low risk of detection bias. </p> </section> <section id="CD007077-sec-0089"> <h6 class="title">2.4 Cause‐specific survival</h6> <p>Six of seven studies contributing data to C‐SS were at high risk of bias for lack of blinding for outcome assessors. </p> </section> <section id="CD007077-sec-0090"> <h6 class="title">2.5 Distant metastasis‐free survival</h6> <p>Five of seven studies contributing data to DM‐FS were at high risk of bias for lack of blinding for outcome assessors. </p> </section> <section id="CD007077-sec-0091"> <h6 class="title">2.6 Relapse‐free survival</h6> <p>Four of six studies contributing data to R‐FS were at high risk of bias for lack of blinding for outcome assessors. </p> </section> <section id="CD007077-sec-0092"> <h6 class="title">2.7 Locoregional recurrence‐free survival</h6> <p>All studies contributing data to this outcome were at high risk of bias for lack of blinding for outcome assessors. </p> </section> <section id="CD007077-sec-0093"> <h6 class="title">2.8 Subsequent mastectomy</h6> <p>All studies contributing data to this outcome were at low risk of bias for detection bias. </p> </section> <section id="CD007077-sec-0094"> <h6 class="title">2.9 Compliance</h6> <p>This outcome was deemed at low risk of bias.</p> </section> <section id="CD007077-sec-0095"> <h6 class="title">2.10 Costs</h6> <p>Deemed at low risk of bias.</p> </section> <section id="CD007077-sec-0096"> <h6 class="title">2.11 Quality of life (using trial‐specific instruments)</h6> <p>All studies contributing data to this outcome were at high risk of bias for lack of blinding for outcome assessors. </p> </section> <section id="CD007077-sec-0097"> <h6 class="title">2.12 Consumer preference</h6> <p>None of the studies assessed consumer preference.</p> </section> </section> </section> </section> <section id="CD007077-sec-0098"> <h3 class="title" id="CD007077-sec-0098">Effects of interventions</h3> <p>See: <a href="./full#CD007077-tbl-0001"><b>Summary of findings 1</b> Summary of Findings Table ‐ PBI?APBI compared to WBRT for early breast cancer</a> </p> <section id="CD007077-sec-0099"> <h4 class="title">Primary outcomes</h4> <section id="CD007077-sec-0100"> <h5 class="title">1.1 Local recurrence‐free survival in the ipsilateral breast</h5> <p>There were 630 local recurrences in the 13,168 women in eight studies.</p> <p>The use of PBI/APBI probably slightly reduces LR‐RFS (HR 1.21, 95% CI 1.03 to 1.42; I<sup>2</sup> = 27%; P = 0.21; moderate‐certainty evidence, downgraded for imprecision; <a href="./references#CD007077-fig-0007" title="">Analysis 1.1</a>; <a href="#CD007077-fig-0003">Figure 3</a>). There was little evidence of heterogeneity on visual inspection and statistical testing. The mean effect of the use of PBI is associated with three more local recurrences per 1000 participants at five years (the true value lies between zero and six more). </p> <div class="figure" id="CD007077-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.1 Local recurrence‐free survival." data-id="CD007077-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.1 Local recurrence‐free survival. </p> </div> </div> </div> <p>All studies were at low risk of bias for this outcome, so a sensitivity analysis was not performed. </p> </section> <section id="CD007077-sec-0101"> <h5 class="title">1.2 Cosmesis</h5> <p>Cosmetic outcome is probably worse with PBI/APBI versus WBRT.</p> <p> <ol id="CD007077-list-0013"> <li> <p>Participant‐reported (OR 2.08, 95% CI 1.68 to 2.57; I<sup>2</sup> = 91%, P = 0.0008; moderate‐certainty evidence, downgraded for risk of detection bias and heterogeneity; <a href="./references#CD007077-fig-0008" title="">Analysis 1.2</a>). We identified 453 events in 2775 participants from two studies (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>). </p> </li> <li> <p>Physician or trained nurse observer‐reported (OR 1.57, 95% CI 1.31 to 1.87; 6 studies, 3652 participants; I<sup>2</sup> = 90%; P &lt; 0.0008; moderate‐certainty evidence, downgraded for lack of blinding and heterogeneity; <a href="./references#CD007077-fig-0009" title="">Analysis 1.3</a>). There was evidence of heterogeneity. We studied 616 events in 3652 participants in six studies. The mean effect of the use of PBI is associated with 63 more adverse cosmetic outcomes per 1000 participants (the true value lies between 35 and 92 more). </p> </li> </ol> </p> <p>We performed a sensitivity analysis by excluding studies at high risk of bias for blinding of outcome assessors for subjective outcomes for physician‐reported cosmesis (<a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>). We found cosmesis was probably worse with PBI/APBI versus WBRT (OR 1.83, 95% CI 1.51 to 2.24; I<sup>2</sup> = 93%; P = 0.00001). There may be some heterogeneity. </p> <p>The planned subgroup analyses were not possible.</p> </section> </section> <section id="CD007077-sec-0102"> <h4 class="title">Secondary outcomes</h4> <section id="CD007077-sec-0103"> <h5 class="title">2.1 Overall survival</h5> <p>The use of PBI/APBI versus WBRT probably makes little or no difference to survival with 1052 deaths in eight studies with 13,175 participants (HR 0.99, 95% CI 0.88 to 1.12; I<sup>2</sup> = 0%; P = 0.27; high‐certainty evidence; <a href="./references#CD007077-fig-0010" title="">Analysis 1.4</a>; <a href="#CD007077-fig-0004">Figure 4</a>). The mean effect of the use of PBI is associated with 0 fewer deaths per 1000 participants at five years (the true value lies between six fewer and six more). There was no heterogeneity on either visual inspection or statistical testing. </p> <div class="figure" id="CD007077-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.3 Overall survival." data-id="CD007077-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.3 Overall survival. </p> </div> </div> </div> </section> <section id="CD007077-sec-0104"> <h5 class="title">2.2 Toxicity</h5> <section id="CD007077-sec-0105"> <h6 class="title">2.2.1 Acute radiotherapy toxicity</h6> <p>PBI/APBI probably reduces acute skin toxicity compared with WBRT (OR 0.76, 95% CI 0.66 to 0.88; I<sup>2</sup> = 99%; P &lt; 0.00001; moderate‐certainty evidence, downgraded for lack of blinding and heterogeneity; <a href="./references#CD007077-fig-0011" title="">Analysis 1.5</a>). We studied 834 events in 3925 participants in four studies. The mean effect of the use of PBI is associated with 46 fewer Grade II or greater toxicity events per 1000 participants (the true value lies between 67 fewer and 22 fewer). There was evidence of heterogeneity. </p> <p>There was no difference in haematomas needing surgical aspiration between APBI and WBRT (P = 0.338; figure from text; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). </p> <p>Seromas needing greater than three aspirations were more frequent with APBI compared with WBRT (P = 0.012; figure from text; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). </p> <p>There was no difference in infection requiring intravenous antibiotics or surgical intervention between APBI and WBRT (P = 0.292; figure from text; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). </p> <p>There was no difference in skin breakdown or delayed healing between APBI and WBRT (P = 0.155; figure from text; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). The mean effect of the use of PBI is associated with 15 fewer late RT toxicity episodes per 1000 participants (the true value lies between 25 fewer and three more). </p> </section> <section id="CD007077-sec-0106"> <h6 class="title">2.2.2 Late radiotherapy toxicity</h6> <p>Late skin toxicity may increase with PBI/APBI versus WBRT (OR 2.27, 95% CI 1.63 to 3.15; 3 studies, 3465 participants; I² = 93%; P &lt; 0.00001; low‐certainty evidence, downgraded for risk of detection bias, heterogeneity and imprecision; <a href="./references#CD007077-fig-0012" title="">Analysis 1.6</a>). </p> <p>Telangiectasia may be worse with PBI/APBI compared with PBI (OR 4.40, 95% CI 3.34 to 5.80; 2 studies, 3010 participants; low‐certainty evidence, downgraded for risk of detection bias and heterogeneity; <a href="./references#CD007077-fig-0013" title="">Analysis 1.7</a>). The mean effect of the use of PBI is associated with 129 more telangiectasia episodes per 1000 participants (the true value lies between 93 more and 317 more). </p> <p>PBI/APBI may increase fat necrosis compared with WBRT (OR 2.76, 95% CI 1.74 to 4.38; 4 studies, 3565 participants; I<sup>2</sup> = 50%; moderate‐certainty evidence, downgraded for lack of blinding and imprecision; <a href="./references#CD007077-fig-0014" title="">Analysis 1.8</a>). The mean effect of the use of PBI is associated with 25 more fat necrosis events per 1000 participants (the true value lies between 11 more and 48 more). There was some heterogeneity. </p> <p>PBI/APBI may increase subcutaneous fibrosis compared with WBRT (OR 5.07, 95% CI 3.81 to 6.74; 2 studies, 3011 participants; moderate‐certainty evidence, downgraded for risk of detection bias and heterogeneity; <a href="./references#CD007077-fig-0015" title="">Analysis 1.9</a>). The mean effect of the use of PBI is associated with 141 more subcutaneous fibrosis events per 1000 participants (the true value lies between 102 and 188 more). </p> <p>Breast pain may increase with PBI/APBI versus WBRT (OR 1.81, 95% CI 1.15 to 2.86; 2 studies, 3012 participants; low‐certainty evidence, downgraded for lack of blinding, heterogeneity and imprecision; <a href="./references#CD007077-fig-0016" title="">Analysis 1.10</a>). <a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> reported no difference in breast pain (data not shown). Breast pain was reduced with PBI compared with WBRT in <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> (P = 0.04; figures from text). </p> </section> </section> <section id="CD007077-sec-0107"> <h5 class="title">2.3 New primary tumours in ipsilateral breast, 'elsewhere primaries'</h5> <p>New primaries in the treated breast may increase with PBI/APBI compared with WBRT (OR 2.82, 95% CI 1.55 to 5.12; I<sup>2</sup> = 76%; P = 0.005; low‐certainty evidence, downgraded for possible inconsistency and imprecision; <a href="./references#CD007077-fig-0017" title="">Analysis 1.11</a>). There were 55 events in 5144 participants in four studies. The mean effect of the use of PBI is associated with 9 more "elsewhere primaries" per 1000 participants (the true value lies between 3 more and 19 more). There was evidence of heterogeneity. </p> </section> <section id="CD007077-sec-0108"> <h5 class="title">2.4 Cause‐specific survival</h5> <p>We found that C‐SS is probably similar with PBI/APBI versus WBRT (HR 1.06, 95% CI 0.83 to 1.36; 7 studies, 9865 participants; I<sup>2</sup> = 0%; P = 0.93; moderate‐certainty evidence, downgraded for lack of blinding and imprecision; <a href="./references#CD007077-fig-0018" title="">Analysis 1.12</a>; <a href="#CD007077-fig-0005">Figure 5</a>). The mean effect of the use of PBI is associated with 1 more breast cancer death per 1000 participants at five years (the true value lies between 3 fewer and 6 more). We found no evidence of heterogeneity on either visual inspection or statistical testing. </p> <div class="figure" id="CD007077-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.8 Cause‐specific survival." data-id="CD007077-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.8 Cause‐specific survival. </p> </div> </div> </div> </section> <section id="CD007077-sec-0109"> <h5 class="title">2.5 Distant metastasis‐free survival</h5> <p>The use of PBI/APBI versus WBRT probably makes little or no difference to DM‐FS (HR 0.95, 95% CI 0.80 to 1.13; 7 studies, 11,033 participants; I<sup>2</sup> = 25%; P = 0.24; moderate‐certainty evidence, downgraded for high risk of detection bias for lack of blinding and imprecision; <a href="./references#CD007077-fig-0019" title="">Analysis 1.13</a>; <a href="#CD007077-fig-0006">Figure 6</a>). The mean effect of the use of PBI is associated with 1 fewer metastatic event per 1000 participants at five years (the true value lies between 6 fewer and 4 more). There was no heterogeneity with either visual inspection or statistical testing. </p> <div class="figure" id="CD007077-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.9 Distant metastasis‐free survival." data-id="CD007077-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.9 Distant metastasis‐free survival. </p> </div> </div> </div> </section> <section id="CD007077-sec-0110"> <h5 class="title">2.6 Relapse‐free survival</h5> <p>The use of PBI/APBI versus WBRT probably decreases RF‐S (HR 1.25, 95% CI 1.05 to 1.48; 6 studies; 11,756 participants; I<sup>2</sup> = 0%; P = 0.61; moderate‐certainty evidence, downgraded for high risk of detection bias for lack of blinding and imprecision.; <a href="./references#CD007077-fig-0020" title="">Analysis 1.14</a>). The mean effect of the use of PBI is associated with 29 more breast cancer relapses per 1000 participants at five years (the true value lies between 8 more and 43 more). We found little evidence of heterogeneity. </p> </section> <section id="CD007077-sec-0111"> <h5 class="title">2.7 Locoregional recurrence‐free survival</h5> <p>L‐RR‐FS may be decreased with PBI/APBI compared with WBRT (HR 1.36, 95% CI 1.06 to 1.74; 5 studies; 6718 participants; I<sup>2</sup> = 69%; P = 0.01; low‐certainty evidence, downgraded for lack of blinding, heterogeneity and imprecision; <a href="./references#CD007077-fig-0021" title="">Analysis 1.15</a>). The mean effect of the use of PBI is associated with 9 more locoregional relapses per 1000 participants at five years (the true value lies between 1 more and 12 more). We found evidence of heterogeneity. </p> </section> <section id="CD007077-sec-0112"> <h5 class="title">2.8 Subsequent mastectomy</h5> <p>Subsequent mastectomy rate is little or no different with PBI/APBI compared with WBRT (OR 0.98, 95% CI 0.78 to 1.23; 3 studies, 3740 participants; I<sup>2</sup> = 0%; P = 0.54; high‐certainty evidence; <a href="./references#CD007077-fig-0022" title="">Analysis 1.16</a>). The mean effect of the use of PBI is associated with 2 fewer mastectomies per 1000 participants (the true value lies between 20 fewer and 20 more). There were 350 events in 3740 participants in three studies. There was no evidence of heterogeneity. </p> </section> <section id="CD007077-sec-0113"> <h5 class="title">2.9 Compliance</h5> <p>Nine studies found that 94.9% of women randomised to PBI/APBI received treatment. For those women randomised to receive WBRT, 95.6% of women received the planned RT. </p> </section> <section id="CD007077-sec-0114"> <h5 class="title">2.10 Costs</h5> <p>Secondary analysis of the <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> data reports conflicting findings: in the UK setting, a modelling‐based study using participant level data found for the pre‐pathology stratum, APBI (using <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> intra‐operative technique) is less costly, with similar quality adjusted life years (QALYs) than whole breast irradiation (<a href="./references#CD007077-bbs2-0098" title="VaidyaJS , WenzF , BulsaraM , et al. Health Technology Assessment, No. 20.73. 2016, Chapter 6. ncbi.nlm.nih.gov/books/NBK3902662016.">Vaidya 2016a</a>). In the United States setting, APBI (using <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> intra‐operative technique) is less costly (<a href="./references#CD007077-bbs2-0028" title="AlvaradoMD , MohanAJ , EssermanLJ , ParkCC , HarrisonBL , HoweRJ , et al. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Annals of Surg Oncology2013;20:2873–80. [DOI: 10.1245/s10434-013-2997-3]">Alvarado 2013</a>; <a href="./references#CD007077-bbs2-0087" title="ShahC , BadiyanS , KhwajaS , ShahH , ChitaliaA , NanavatiA , et al. Evaluating radiotherapy options in breast cancer: does intraoperative radiotherapy represent the most cost-efficacious option?Clinical Breast Cancer2014;14:141-6. [DOI: 10.1016/j.clbc.2013.10.005]">Shah 2014</a>) and associated with more (<a href="./references#CD007077-bbs2-0028" title="AlvaradoMD , MohanAJ , EssermanLJ , ParkCC , HarrisonBL , HoweRJ , et al. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Annals of Surg Oncology2013;20:2873–80. [DOI: 10.1245/s10434-013-2997-3]">Alvarado 2013</a>) or fewer (<a href="./references#CD007077-bbs2-0087" title="ShahC , BadiyanS , KhwajaS , ShahH , ChitaliaA , NanavatiA , et al. Evaluating radiotherapy options in breast cancer: does intraoperative radiotherapy represent the most cost-efficacious option?Clinical Breast Cancer2014;14:141-6. [DOI: 10.1016/j.clbc.2013.10.005]">Shah 2014</a>) QALYs. </p> </section> <section id="CD007077-sec-0115"> <h5 class="title">2.11 Quality of life</h5> <p>At baseline, both PBI/APBI and WBRT participants (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>) had similar EORTC QLQ‐C30 and QLQ‐BR23 (<a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>), and Global Health score (GHS) (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>) (see <a href="#CD007077-tbl-0012">Table 11</a>). </p> <p>Assessment at two years' follow‐up revealed that participants in the PBI/APBI arms had better QLQ‐C30 in most domains (except dyspnoea, constipation and diarrhoea) and better QLQ‐BR23 in most domains (except sexual functioning, sexual enjoyment and hair loss) in the PBI/APBI arm (<a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>) (<a href="#CD007077-tbl-0012">Table 11</a>). Breast symptoms were increased (in a clinically relevant amount) for participants in the WBRT arm (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>). </p> <p>At five years follow‐up, GHS scores did not differ between women receiving APBI/PBI and WBRT (P = 0.95; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>). Breast symptoms were increased (in a clinically relevant amount) for participants in the WBRT arm (<a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>). There was no difference between study arms for body image at five years' follow‐up (<a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>). Quality of life was assessed in <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> but has not been reported yet. </p> </section> <section id="CD007077-sec-0116"> <h5 class="title">2.12 Consumer preference</h5> <p>There were no data on consumer preference.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007077-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007077-sec-0117"></div> <section id="CD007077-sec-0118"> <h3 class="title" id="CD007077-sec-0118">Summary of main results</h3> <p>LR‐FS is probably slightly worse with APBI/PBI, but there appears to be little detriment or difference to other oncological outcomes including survival. R‐FS probably decreases and L‐RR‐FS may be decreased with APBI/PBI. The cosmetic outcome is probably worse with APBI/PBI. APBI appears to make little or no difference to mastectomy rate, and primaries in the ipsilateral breast 'elsewhere primaries' may be increased. The economic and psychological impact of the increase in 'elsewhere primaries' is uncertain. </p> </section> <section id="CD007077-sec-0119"> <h3 class="title" id="CD007077-sec-0119">Overall completeness and applicability of evidence</h3> <p>There were limitations in completeness and applicability of evidence due to clinical heterogeneity between the trials, duration of follow‐up and little or no useful information available for some outcome measures. </p> <section id="CD007077-sec-0120"> <h4 class="title">Clinical heterogeneity between the trials</h4> <p>There was evident clinical heterogeneity in both the study participants and the interventions.</p> <p>The PBI/APBI delivered was heterogeneous in dose, technique, fractionation and target delineation. </p> <p> <ol id="CD007077-list-0014"> <li> <p>The RT doses varied between the trials. In six of eight studies, the EQD<sub>2</sub> delivered in the APBI arm was equivalent or within 5% of the WBRT dose (except for <a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> and <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>; see <a href="#CD007077-tbl-0011">Table 10</a>). Despite the dose equivalence in the APBI arm, we found that LR‐FS was probably slightly worse with APBI, which suggests there may be technical issues with RT delivery (e.g. target volume definition or target coverage). </p> </li> <li> <p>The RT techniques used to deliver PBI/APBI varied (see <a href="#CD007077-tbl-0009">Table 8</a>). </p> </li> <li> <p>The trials differed in fractionation used; all the studies used greater than 2 Gy per fraction in the experimental arm, except for <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>, where some women in the PBI/APBI arm received 2 Gy per fraction (see <a href="#CD007077-tbl-0011">Table 10</a>). </p> </li> <li> <p>The techniques used to define the target volume in <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>, <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>, <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>, <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a>, and <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> were consistent with current practice, but <a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> provided inadequate details for the technique used in to be certain of this (see <a href="#CD007077-tbl-0009">Table 8</a>). </p> </li> </ol> </p> <p>Avoiding geographic miss is imperative in RT. Delivery of RT is a technical exercise. <a href="./references#CD007077-bbs2-0077" title="PetersLJ , O'SullivanB , GiraltJ , FitzgeraldTJ , TrottiA , BernierJ , et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer; results from TROG 02.02. Journal of Clinical Oncology2010;28(18):2996-3001.">Peters 2010</a> demonstrated the extremely important role that quality assurance plays in the delivery of high‐quality RT. Poor‐quality RT (a non‐compliant plan) for locally advanced head and neck cancer was associated with a 20% detriment in survival and a 29% detriment to locoregional control (<a href="./references#CD007077-bbs2-0077" title="PetersLJ , O'SullivanB , GiraltJ , FitzgeraldTJ , TrottiA , BernierJ , et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer; results from TROG 02.02. Journal of Clinical Oncology2010;28(18):2996-3001.">Peters 2010</a>). Four studies did not mention quality assurance (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). Although <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> assessed implant quality, less than 20% of the implants had postimplant CT to document planning target volume (PTV) coverage and quality assurance for APBI using electrons or WBRT was not mentioned (see <a href="./references#CD007077-sec-0152" title="">Characteristics of included studies</a> table). <a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> and <a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> included an extensive quality assurance programme with credentialing, real‐time and post‐hoc review of radiation quality. <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> had rigorous pre‐ and postimplant quality assurance procedures. </p> <p>The lack of precision in target definition, the variety of methods used to deliver PBI/APBI (even within the experimental arm of the trials; see <a href="#CD007077-tbl-0009">Table 8</a>) and the omission of robust quality assurance mean that the RT delivered in some trials was not reproducible. We cannot be certain of the dose delivered and the volume of breast treated. </p> <p>We found there was heterogeneity for the outcome of cosmesis (physician‐reported). There were some possible sources of clinical heterogeneity that may have contributed to this: in <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>, 40/128 (30%) women in the PBI/APBI arm received 50 Gy in 25 fractions to the tumour bed using EBRT; these women who had conventionally fractionated RT at the same dose as the WBRT arm were likely to have very similar cosmetic outcome. <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> delivered PBI/APBI using IMRT, with careful dose constraints applied: we know that use of IMRT for WBRT is associated with improvement in cosmetic outcome (<a href="./references#CD007077-bbs2-0039" title="DonovanE , BleakleyN , DenholmE , EvansP , GothardL , HansonJ , et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiotherapy and Oncology2007;82(3):254-64.">Donovan 2007</a>; <a href="./references#CD007077-bbs2-0078" title="PignolJP , OlivottoI , RakovitchE , GardnerS , SixelK , BeckhamW , et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. Journal of Clinical Oncology2008;26(13):2085-92.">Pignol 2008</a>). </p> <p>Modern breast‐conserving therapy with postoperative WBRT achieves local control rates of 3.3% to 3.4% at five years and 5.2% to 6.7% at 10 years (<a href="./references#CD007077-bbs2-0052" title="HavilandJS , OwenJR , DewarJA , AgrawalRK , BarrettJ , Barrett-LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncology2013;14:1086-94.">Haviland 2013</a>). With careful participant selection (aged 65 years or greater, T1‐2 tumours, 3 cm or less, margin negative, oestrogen receptor‐positive and all receiving tamoxifen), surgery alone can achieve local recurrence rates of 4.1% at five years (<a href="./references#CD007077-bbs2-0063" title="KunklerIH , WilliamsLJ , JackWJ , CameronDA , DixonJM , PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncology2015;16(3):266-73.">Kunkler 2015</a>). The risk of local recurrence continues with longer follow‐up, in modern series where women with good prognosis were treated with surgery alone, the 10‐year risk of locoregional or distant recurrence was 19.9% (reduced to 6.3% with RT; <a href="./references#CD007077-bbs2-0031" title="BlameyRW , BatesT , ChettyU , DuffySW , EllisIO , GeorgeD , et al. Radiotherapy and/or tamoxifen after breast conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. European Journal of Cancer2013;49:2294-302.">Blamey 2013</a>; <a href="./references#CD007077-bbs2-0043" title="FisherB , AndersonS , BryantJ , MargoleseRG , DeutschM , FisherER , et al. Twenty-year follow-up of a randomised trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine2002;347(16):1233-41.">Fisher 2002</a>; <a href="./references#CD007077-bbs2-0046" title="FylesAW , McCreadyDR , ManchulLA , TrudeauME , MeranteP , PintilieM , et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. New England Journal of Medicine2004;351:963-70.">Fyles 2004</a>; <a href="./references#CD007077-bbs2-0058" title="HughesKS , SchnaperLA , BerryD , CirrincioneCT , BerryDA , McCormickB , et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. New England Journal of Medicine2004;351:971-7.">Hughes 2004</a>; <a href="./references#CD007077-bbs2-0081" title="PotterR , GnantM , KwasnyW , TauschC , Handl-ZellerL , PakischB , et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. International Journal of radiation Oncology, Biology, Physics2007;68:334-40.">Potter 2007</a>; <a href="./references#CD007077-bbs2-0082" title="PrescottRJ , KunklerJH , WilliamsLJ , KingCC , JackW , van derPolM , et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technology Assessment2007;11(i-x):1-170.">Prescott 2007</a>; <a href="./references#CD007077-bbs2-0109" title="WinzerKJ , SauerbreiW , BraunM , LierschT , DunstJ , GuskiH , et al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2x2 randomised clinical trial in patients with low risk of recurrence. European Journal of Cancer2010;46(1):95-101.">Winzer 2010</a>). Even if PBI/APBI is poorly targeted, in a low‐risk population being treated with systemic therapy (which greatly improves local control) (<a href="./references#CD007077-bbs2-0033" title="BurskinHS , CuriglianoG , LoiblS , WinerE , ThurlimannB , DurskyP . Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Annals of Oncology2019;30(10):1541-57.">Burskin 2019</a>), low local recurrence rates can be expected. </p> <p>The paradigm for PBI/APBI relies on the basis that WBRT does not reduce the number of 'elsewhere primaries' within the treated breast, but we found that PBI/APBI may cause an increase in 'elsewhere primaries' (OR 1.77, 95% CI 1.07 to 2.92; <a href="./references#CD007077-fig-0017" title="">Analysis 1.11</a>). </p> <p>These data do not apply to women who have had oncoplastic surgery.</p> </section> <section id="CD007077-sec-0121"> <h4 class="title">Duration of follow‐up</h4> <p>The length of follow‐up in the included trials was adequate to detect local recurrences (10 years (<a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>), 69 months (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>), 10.7 years (<a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>), 60 months (<a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a>), 72.2 months (<a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a>), 79.2 months (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>), 103.2 months (<a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>)). Local recurrences continue to increase over time (at about 1% per year), as can be seen in the START data: 3.3% to 3.4% at five years and 5.2% to 6.7% at 10 years (<a href="./references#CD007077-bbs2-0052" title="HavilandJS , OwenJR , DewarJA , AgrawalRK , BarrettJ , Barrett-LeePJ , et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncology2013;14:1086-94.">Haviland 2013</a>). Any effect on breast C‐SS related to local control requires much longer follow‐up (<a href="./references#CD007077-bbs2-0041" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet2011;378(9804):1707-16.">EBCTCG 2011</a>). None of the included trials had sufficient follow‐up to report meaningful OS results. </p> <p>We know that RT reduces the risk of any first recurrence, and although the proportional reduction is most evident in the first year after treatment, it is still present in years five to nine (RR 0.59, 95% CI 0.5 to 0.7; <a href="./references#CD007077-bbs2-0041" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet2011;378(9804):1707-16.">EBCTCG 2011</a>). Even in modern studies that included low‐risk women treated with lumpectomy (enrolled after 1989), the 10‐year risk of locoregional and distant recurrence was 19.9% (reduced to 6.3% with RT; <a href="./references#CD007077-bbs2-0031" title="BlameyRW , BatesT , ChettyU , DuffySW , EllisIO , GeorgeD , et al. Radiotherapy and/or tamoxifen after breast conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. European Journal of Cancer2013;49:2294-302.">Blamey 2013</a>; <a href="./references#CD007077-bbs2-0043" title="FisherB , AndersonS , BryantJ , MargoleseRG , DeutschM , FisherER , et al. Twenty-year follow-up of a randomised trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine2002;347(16):1233-41.">Fisher 2002</a>; <a href="./references#CD007077-bbs2-0046" title="FylesAW , McCreadyDR , ManchulLA , TrudeauME , MeranteP , PintilieM , et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. New England Journal of Medicine2004;351:963-70.">Fyles 2004</a>; <a href="./references#CD007077-bbs2-0058" title="HughesKS , SchnaperLA , BerryD , CirrincioneCT , BerryDA , McCormickB , et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. New England Journal of Medicine2004;351:971-7.">Hughes 2004</a>; <a href="./references#CD007077-bbs2-0081" title="PotterR , GnantM , KwasnyW , TauschC , Handl-ZellerL , PakischB , et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. International Journal of radiation Oncology, Biology, Physics2007;68:334-40.">Potter 2007</a>; <a href="./references#CD007077-bbs2-0082" title="PrescottRJ , KunklerJH , WilliamsLJ , KingCC , JackW , van derPolM , et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technology Assessment2007;11(i-x):1-170.">Prescott 2007</a>; <a href="./references#CD007077-bbs2-0109" title="WinzerKJ , SauerbreiW , BraunM , LierschT , DunstJ , GuskiH , et al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2x2 randomised clinical trial in patients with low risk of recurrence. European Journal of Cancer2010;46(1):95-101.">Winzer 2010</a>). Even women at low risk of recurrence (if they are at risk for another 30 years) are likely to have increases in recurrence with longer follow‐up. The use of PBI/APBI may mean they are at risk of 'elsewhere primaries' for this time period. </p> </section> <section id="CD007077-sec-0122"> <h4 class="title">Outcomes measures with little or no useful information</h4> <p>The authors of <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> (completed) indicated that cosmesis, participant satisfaction, health economics and consumer preference will be the subject of a subprotocol and information with respect to these outcomes will be available in the future. The seven ongoing trials that we found are likely to address these outcomes (see <a href="./references#CD007077-sec-0155" title="">Characteristics of ongoing studies</a> table), and more data will be reported for included studies relating to these outcomes in future. </p> </section> </section> <section id="CD007077-sec-0123"> <h3 class="title" id="CD007077-sec-0123">Quality of the evidence</h3> <p>The available evidence does allow for the drawing of robust conclusions in respect of the objective of the review: to determine whether PBI/APBI is equivalent to or better than conventional or hypofractionated WBRT after breast‐conserving therapy for early‐stage breast cancer. We found nine studies and analysed 14,245 of the 15,187 women enrolled. See <a href="./full#CD007077-tbl-0001">summary of findings Table 1</a>. </p> <p>LR‐FS: we did not downgrade for indirectness because the included studies used contemporary RT techniques. We did not downgrade for inconsistency (I<sup>2</sup> = 27%). We downgraded for imprecision; there were more than 300 events (322), and although the optimum information size (OIS) had been met, the CIs did not exclude either clinically unimportant harms or clinically important harms. We did not downgrade for publication bias, given the systematic literature search we had performed. The overall certainty of evidence for LR‐FS was moderate. </p> <p>Cosmesis (physician or nurse reported): we downgraded for risk of bias for lack of blinding of outcome assessors and inconsistency (I<sup>2</sup> = 90%): although all studies used the same four‐point scale. We did not downgrade for indirectness. We did not downgrade for imprecision; OIS was met (there were greater than 300 events (591)) and the CIs excluded the possibility of clinically unimportant effects. We did not downgrade for publication bias given the systematic literature search we had performed. The overall certainty of evidence for cosmesis was moderate. </p> <p>OS: we did not downgrade for risk of bias, indirectness, inconsistency (I<sup>2</sup> = 0%; P = 0.53) or imprecision: OIS was met (the CIs crossed one, but excluded clinically unimportant harms or meaningful benefits). We did not downgrade for publication bias (based on examination of a Funnel plot). The overall certainty of evidence for OS was high. </p> <p>Late RT toxicity (subcutaneous fibrosis): we did not downgrade for indirectness. We downgraded for lack of blinding and inconsistency (I<sup>2</sup> = 89%). We did not downgrade for imprecision (as we reported on more than 300 events). We did not downgrade for publication bias. The overall certainty of evidence for subcutaneous fibrosis was moderate. </p> <p>C‐SS: we did not downgrade for indirectness or inconsistency (I<sup>2</sup> = 0%; P = 0.93). We downgraded for lack of blinding and imprecision, although OIS was met, there were fewer than 300 events (116 events) and the CIs did not include the possibility of clinically significant benefits or harms from PBI/APBI. We did not downgrade for publication bias for this outcome. The overall certainty of evidence for C‐SS was moderate. </p> <p>DM‐FS: we did not downgrade for risk of indirectness or inconsistency (I<sup>2</sup> = 25%; P = 0.24). We downgraded for lack of blinding and imprecision: although OIS was met, there were fewer than 300 events (123 events) and the CIs included clinical meaningful benefits and clinically insignificant harms. We did not downgrade for publication bias. The overall certainty of evidence for DM‐FS was moderate. </p> <p>Subsequent mastectomy: we did not downgrade for risk of bias. We did not downgrade for indirectness or inconsistency (I<sup>2</sup> = 0%; P = 0.54). We downgraded for imprecision: although OIS was met, and there were more than 300 events (350) and the CIs did not exclude clinically meaningful benefits or insignificant harms. The overall certainty of evidence for subsequent mastectomy was low. </p> </section> <section id="CD007077-sec-0124"> <h3 class="title" id="CD007077-sec-0124">Potential biases in the review process</h3> <p>We consider that we have identified all the relevant completed RCTs. For reporting of adverse effects, the precision was low because the OIS was not met. This may improve in future updates, as more information with respect to these outcomes is reported. </p> <p>We included 1031/14,319 (7%) women who had DCIS in this study population.</p> </section> <section id="CD007077-sec-0125"> <h3 class="title" id="CD007077-sec-0125">Agreements and disagreements with other studies or reviews</h3> <p>We found nine systematic reviews comparing PBI/APBI with WBRT.</p> <p>We found one meta‐analysis (<a href="./references#CD007077-bbs2-0099" title="ValachisA , MauriD , PolyzosNP , MavroudisD , GeorgouliasV , CasazzaG . Partial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trials. Breast Journal2010;16(3):245-51.">Valachis 2010</a>), which included one study (<a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>) in common with our systematic review and recruited 1140 women (<a href="./references#CD007077-bbs2-0010" title="DodwellDJ , DykerK , BrownJ , HawkinsK , CohenD , SteadM , et al. A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clinical Oncology2005;17(8):618-22. ">Dodwell 2005</a>; <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0014" title="MageeB , SwindellR , HarrisM , BanerjeeSS . Prognostic factors for breast recurrence after conservative breast surgery and radiotherapy: results from a randomised trial. Radiotherapy and Oncology1996;39(3):223-7. RibeiroGG , DunnG , SwindellR , HarrisM , BanerjeeSS . Conservation of the breast using two different radiotherapy techniques: interim report of a clinical trial. Clinical Oncology1990;2(1):27-34. RibeiroGG , MageeB , SwindellR , HarrisM , BanerjeeSS . The Christie Hospital breast conservation trial: an update at 8 years from inception. Clinical Oncology1993;5(5):278-83. ">Ribeiro 1993</a>). They found no difference for mortality (OR 0.91, 95% CI 0.67 to 1.23; P = 0.55) and distant metastasis (OR 0.74, 95% CI 0.51 to 1.08; P = 0.12) for the comparison of PBI/APBI versus WBRT. PBI/APBI was associated with increased local recurrence (OR 2.15, 95% CI 1.40 to 3.31; P = 0.001) and axillary recurrence (OR 3.43, 95% CI 2.06 to 5.71; P &lt; 0.0001) when compared with WBRT. They concluded that PBI does not seem to jeopardise survival and may be used as an alternative to WBRT (<a href="./references#CD007077-bbs2-0099" title="ValachisA , MauriD , PolyzosNP , MavroudisD , GeorgouliasV , CasazzaG . Partial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trials. Breast Journal2010;16(3):245-51.">Valachis 2010</a>). The authors pooled the data from the trials (see <a href="#CD007077-sec-0039">Data synthesis</a> section). </p> <p>We found one systematic review (search date 2010; <a href="./references#CD007077-bbs2-0032" title="BlueCross BlueShield Association. Accelerated partial breast irradiation as sole radiotherapy after breast-conserving surgery for early stage breast cancer – executive summary. Technology Assessment Central Assessment Program2007;22(4):1-4.">BlueCross BlueShield</a>). They included two RCTs (<a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a>; <a href="./references#CD007077-bbs2-0014" title="MageeB , SwindellR , HarrisM , BanerjeeSS . Prognostic factors for breast recurrence after conservative breast surgery and radiotherapy: results from a randomised trial. Radiotherapy and Oncology1996;39(3):223-7. RibeiroGG , DunnG , SwindellR , HarrisM , BanerjeeSS . Conservation of the breast using two different radiotherapy techniques: interim report of a clinical trial. Clinical Oncology1990;2(1):27-34. RibeiroGG , MageeB , SwindellR , HarrisM , BanerjeeSS . The Christie Hospital breast conservation trial: an update at 8 years from inception. Clinical Oncology1993;5(5):278-83. ">Ribeiro 1993</a> (which we excluded)) and seven non‐RCTs. They concluded that "the body of evidence on interstitial PBI/APBI compared to conventional whole‐breast irradiation is weak, and it is extremely weak (i.e. no comparative studies) for balloon brachytherapy, intraoperative PBI/APBI, and external‐beam PBI/APBI. The data on PBI/APBI compared to whole‐breast irradiation are insufficient to draw any conclusions about the relative effectiveness of these modalities. Furthermore, it is becoming increasingly clear that each type of PBI/APBI should be judged on its own merits, and studies comparing different PBI/APBI techniques to each other as well as to whole‐breast irradiation are needed" (<a href="./references#CD007077-bbs2-0032" title="BlueCross BlueShield Association. Accelerated partial breast irradiation as sole radiotherapy after breast-conserving surgery for early stage breast cancer – executive summary. Technology Assessment Central Assessment Program2007;22(4):1-4.">BlueCross BlueShield</a>). </p> <p>We found one review that used a systematic search (search date February 2014; <a href="./references#CD007077-bbs2-0069" title="MartaGN , MacedoCR , deAndrade CarvalhoH , HannaAS , Fernandes da SilvaJL , RieraR . Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. Radiotherapy and Oncology2015;114:42-9.">Marta 2015</a>). Our review differed in that we included updated data for <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> and they included <a href="./references#CD007077-bbs2-0010" title="DodwellDJ , DykerK , BrownJ , HawkinsK , CohenD , SteadM , et al. A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clinical Oncology2005;17(8):618-22. ">Dodwell 2005</a> and <a href="./references#CD007077-bbs2-0014" title="MageeB , SwindellR , HarrisM , BanerjeeSS . Prognostic factors for breast recurrence after conservative breast surgery and radiotherapy: results from a randomised trial. Radiotherapy and Oncology1996;39(3):223-7. RibeiroGG , DunnG , SwindellR , HarrisM , BanerjeeSS . Conservation of the breast using two different radiotherapy techniques: interim report of a clinical trial. Clinical Oncology1990;2(1):27-34. RibeiroGG , MageeB , SwindellR , HarrisM , BanerjeeSS . The Christie Hospital breast conservation trial: an update at 8 years from inception. Clinical Oncology1993;5(5):278-83. ">Ribeiro 1993</a> (which we excluded). They reported decreased local control with APBI versus WBRT (HR 4.54, 95% CI 1.78 to 11.61; P = 0.002). They concluded that APBI was associated with an increase in local recurrence, but found no difference in other outcomes. </p> <p><a href="./references#CD007077-bbs2-0060" title="KongL , ChengJ , DingX , LiB , ZhangJ , LiH , et al. Efficacy and safety of accelerated partial breast irradiation after breast-conserving surgery: a meta-analysis of published comparative studies. Breast Journal2014;20(2):116.">Kong 2014</a> performed a systematic search (search date June 2012) including 10 studies, and included two retrospective cohorts, two matched pair analyses and three prospective cohort studies. They found that PBI/APBI was associated with increased local recurrence (OR 1.54, 95% CI 1.15 to 2.06; P = 0.004). They found no difference for the comparison of PBI/APBI for the outcomes of distant metastases, OS and disease‐free survival. </p> <p>One review by <a href="./references#CD007077-bbs2-0111" title="YeX , BaoS , GuoL , WangX , MaY , ZhangW , et al. Accelerated partial breast irradiation for breast cancer: a meta-analysis. Translational Oncology2013;6(6):619-27.">Ye 2013</a> included 919 women in four studies; their search was not systematic (search date June 2013). They included a matched pair analysis, and the fourth study was not referenced. They reported no difference in local control, but appeared to have double counted the data for <a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> at two time points. They concluded that other outcomes did not differ, although they reported more women who were treated with APBI had good/excellent cosmesis. </p> <p><a href="./references#CD007077-bbs2-0097" title="VaidyaJS , BulsaraM , WenzF , CoombsN , SingerJ , EbbsS , et al. Reduced mortality with partial-breast irradiation for early breast cancer: a meta-analysis of randomized trials. International Journal of Radiation Oncology, Biology, Physics2016;96(2):259-65.">Vaidya 2016</a> (search date November 2015, non‐systematic) included studies in English. For OS, they included four studies and reported 1.3% (95% CI −2.5% to 0.0%) difference in deaths when comparing WBRT and PBI (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>; <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). For C‐SS they included four studies (<a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a>; <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>; <a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a>;<a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>). They concluded that "the use of PBI does not compromise breast cancer or overall mortality." </p> <p>The systematic review by <a href="./references#CD007077-bbs2-0061" title="KorzetsY , FylesA , ShepshelovichD , AmirE , GoldvaserH . Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment2019;175:531-45.">Korzets 2019</a> (search date January 2018) included data from nine studies. Their search was not systematic and limited to English language studies, and evidence was not assessed for risk of bias or quality. They found similar findings for: LR‐FS (HR 1.56, 95% CI 0.97 to 2.52), cosmesis (OR 1.23, 95% CI 0.99 to 1.52), relapse (OR 1.06, 95% CI 0.91 to 1.20) and survival (OR 0.84, 95% CI 0.71 to 1.01). </p> <p><a href="./references#CD007077-bbs2-0103" title="VianiGA , ArrudaCV , FaustinoAC , De FendiLI . Partial-breast irradiation versus whole-breast radiotherapy for early breast cancer: a systematic review and update meta-analysis. Brachytherapy2020;19:491-8.">Viani 2020</a> reported a systematic review and meta‐analysis (search date December 2019). They included 11 RCTs, the nine we reported in our review and <a href="./references#CD007077-bbs2-0010" title="DodwellDJ , DykerK , BrownJ , HawkinsK , CohenD , SteadM , et al. A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clinical Oncology2005;17(8):618-22. ">Dodwell 2005</a> and <a href="./references#CD007077-bbs2-0014" title="MageeB , SwindellR , HarrisM , BanerjeeSS . Prognostic factors for breast recurrence after conservative breast surgery and radiotherapy: results from a randomised trial. Radiotherapy and Oncology1996;39(3):223-7. RibeiroGG , DunnG , SwindellR , HarrisM , BanerjeeSS . Conservation of the breast using two different radiotherapy techniques: interim report of a clinical trial. Clinical Oncology1990;2(1):27-34. RibeiroGG , MageeB , SwindellR , HarrisM , BanerjeeSS . The Christie Hospital breast conservation trial: an update at 8 years from inception. Clinical Oncology1993;5(5):278-83. ">Ribeiro 1993</a> (which we excluded because the RT techniques used do not reflect current practice). They report on 14,436 participants and for local recurrence (LR) at five years (OR 1.46, 95% CI 1.15 to 2.00) and OS (OR 0.96, 95% CI 0.82 to 1.13). Their conclusions agreed with ours: "the LR with partial breast irradiation is low and similar to WBRT in selected early breast cancer patients." </p> <p>Several guidelines have been published on PBI/APBI. The American Society of Therapeutic Radiology and Oncology (ASTRO) consensus evolved because it was clear that many women are treated in the US with PBI/APBI outside clinical trials. They indicated a patient population "suitable" for PBI/APBI outside the context of a clinical trial: women aged 60 years and over, with pT1N0(i‐, i+)M0, margins greater than 2 mm, unifocal disease, oestrogen receptor‐positive, who have had no neoadjuvant therapy. They also described women deemed unsuitable for PBI/APBI. They state that, "patients who choose treatment with PBI/APBI should be informed that whole‐breast irradiation (WBI) is an established treatment with a much longer track record that has documented long‐term effectiveness and safety" (<a href="./references#CD007077-bbs2-0089" title="SmithBD , ArthurDW , BuchholzTA , HafftyBG , HahnCA , HardenberghPH , et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). International Journal of Radiation Oncology, Biology, Physics2009;74(4):987-1001.">Smith 2009</a>). This statement provides guidance in selecting participants who may be appropriate for PBI/APBI outside the context of a clinical trial, but the Task Force strongly endorsed enrolment of all eligible participants considering PBI/APBI onto <a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a> and encouraged enrolment of other participants considering PBI/APBI, particularly those not in the "suitable" group, into prospective clinical studies to address many of the unanswered questions in PBI/APBI (<a href="./references#CD007077-bbs2-0089" title="SmithBD , ArthurDW , BuchholzTA , HafftyBG , HahnCA , HardenberghPH , et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). International Journal of Radiation Oncology, Biology, Physics2009;74(4):987-1001.">Smith 2009</a>). <a href="./references#CD007077-bbs2-0071" title="National Comprehensive Cancer Network. NCCN guidelines version 2.2015 invasive breast cancer. www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed 7 November 2015).">NCCN</a> stated, "patients are encouraged to enter clinical trials, and endorses the ASTRO guidelines." </p> <p>In the absence of an available trial, the American College of Radiology (ACR) Appropriateness Criteria panel recommends following the consensus guidelines of the ASTRO (<a href="./references#CD007077-bbs2-0030" title="BellonJR , HarrisEE , ArthurDW , BaileyL , CareyL , GoyalS , et al. ACR Appropriateness Criteria® conservative surgery and radiation – stage I and II breast carcinoma: expert panel on radiation oncology: breast. Breast Journal2011;17(5):448-55.">Bellon 2011</a>). </p> <p>The <a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> Breast Cancer Working Group recommends three categories guiding patient selection for PBI/APBI: </p> <p> <ol id="CD007077-list-0015"> <li> <p>a low‐risk group for whom PBI/APBI outside the context of a clinical trial is an acceptable treatment option; including participants aged at least 50 years with unicentric, unifocal, pT1‐2 (less than 30 mm) pN0, non‐lobular invasive breast cancer without the presence of an extensive intraductal component (EIC) and lymphovascular invasion (LVI) and with negative surgical margins of at least 2 mm; </p> </li> <li> <p>a high‐risk group, for whom PBI/APBI is considered contraindicated; including participants aged 40 years or less; having positive margins, with or without any of the following pathological features (multicentric or large (greater than 30 mm) tumours, EIC‐positive or LVI‐positive tumours, four or more positive lymph nodes, unknown axillary status (pNx)); and </p> </li> <li> <p>an intermediate‐risk group, for whom PBI/APBI is considered acceptable only in the context of prospective clinical trials (<a href="./references#CD007077-bbs2-0080" title="PolgárC , Van LimbergenE , PötterR , KovácsG , PoloA , LyczekJ , et al. Patient selection for accelerated partial-breast irradiation (PBI/APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiotherapy and Oncology2010;94(3):264-73.">Polgár 2010</a>). </p> </li> </ol> </p> <p>The <a href="./references#CD007077-bbs2-0073" title="National Health Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer: diagnosis and management (NG101), July 2018. nice.org.uk/guidance/ng101 accessed 20 August 2021.">NICE 2018</a> guidelines recommend that PBI can be considered for women treated with breast‐conserving surgery (excluding lobular histology) who have clear margins, are 50 years or older, with tumours 3 cm or less, which are N0, Grade I‐II, oestrogen receptor positive, HER2 negative and who have been advised to have endocrine therapy for five years. NICE recommends using EBRT to deliver PBI and advising women that while the local control (LC) at five years is equivalent to that with WBRT, LC rates at greater than five years are unknown and that the use of PBI may be associated with less late toxicity. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007077-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD007077-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007077-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.1 Local recurrence‐free survival." data-id="CD007077-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.1 Local recurrence‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.3 Overall survival." data-id="CD007077-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.3 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.8 Cause‐specific survival." data-id="CD007077-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.8 Cause‐specific survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.9 Distant metastasis‐free survival." data-id="CD007077-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), outcome: 1.9 Distant metastasis‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 1: Local recurrence‐free survival" data-id="CD007077-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 1: Local recurrence‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 2: Cosmesis (participant‐reported)" data-id="CD007077-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 2: Cosmesis (participant‐reported) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 3: Cosmesis, physician/nurse‐reported" data-id="CD007077-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 3: Cosmesis, physician/nurse‐reported </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 4: Overall survival" data-id="CD007077-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 4: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 5: Acute radiotherapy (RT) skin toxicity" data-id="CD007077-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 5: Acute radiotherapy (RT) skin toxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 6: Late RT skin toxicity" data-id="CD007077-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 6: Late RT skin toxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 7: Telangiectasia (late RT toxicity)" data-id="CD007077-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 7: Telangiectasia (late RT toxicity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 8: Fat necrosis" data-id="CD007077-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 8: Fat necrosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 9: Subcutaneous fibrosis (late RT toxicity)" data-id="CD007077-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 9: Subcutaneous fibrosis (late RT toxicity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 10: Breast pain (late RT toxicity)" data-id="CD007077-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 10: Breast pain (late RT toxicity) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 11: New primary tumours in ipsilateral breast, 'elsewhere primary'" data-id="CD007077-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 11: New primary tumours in ipsilateral breast, 'elsewhere primary' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 12: Cause‐specific survival" data-id="CD007077-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 12: Cause‐specific survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 13: Distant metastasis‐free survival" data-id="CD007077-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 13: Distant metastasis‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 14: Relapse‐free survival" data-id="CD007077-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 14: Relapse‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 15: Locoregional recurrence‐free survival" data-id="CD007077-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 15: Locoregional recurrence‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007077-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/urn:x-wiley:14651858:media:CD007077:CD007077-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 16: Subsequent mastectomy" data-id="CD007077-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_t/tCD007077-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT), Outcome 16: Subsequent mastectomy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/media/CDSR/CD007077/image_n/nCD007077-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007077-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of Findings Table ‐ PBI?APBI compared to WBRT for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PBI/APBI compared to WBRT for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : health problem or population <b>Setting</b> : Academic, tertiary and community practice <b>Intervention</b> : PBI/APBI <b>Comparison</b>: WBRT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with WBRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with PBI/APBI</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Local recurrence‐free survival ‐ total (LR‐FS)<br/>follow up: range 60 months to 103 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 1.21</b><br/>(1.03 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>13168<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a,</sup><sup>b,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>985 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>982 per 1000</b><br/>(979 to 985) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cosmesis, physician/nurse‐reported<br/>assessed with: Harvard scale<br/>follow up: range 60 months to 8.2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>138 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>201 per 1000</b><br/>(173 to 230) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.57</b><br/>(1.31 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3652<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>e,</sup><sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Overall survival<br/>follow up: range 60 months to 103 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.99</b><br/>(0.88 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>13175<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH <sup>c,</sup><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>949 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>949 per 1000</b><br/>(943 to 955) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subcutaneous fibrosis (late RT toxicity)<br/>assessed with: EORTC/RTOG CTCAE and NCI Version 3‐4.0<br/>follow up: median 60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>43 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>184 per 1000</b><br/>(145 to 231) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 5.07</b><br/>(3.81 to 6.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3011<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Cause‐specific survival (C‐SS)<br/>follow up: range 60 months to 103 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 1.06</b><br/>(0.83 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9865<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>i,</sup><sup>j,</sup><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>983 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>982 per 1000</b><br/>(977 to 986) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Distant metastasis‐free survival (DM‐FS)<br/>follow up: range 60 months to 72.2 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>HR 0.95</b><br/>(0.80 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>11033<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>l,</sup><sup>m,</sup><sup>n,</sup><sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>971 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>972 per 1000</b><br/>(967 to 977) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subsequent mastectomy<br/>follow up: median 60 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>97 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>95 per 1000</b><br/>(77 to 116) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.98</b><br/>(0.78 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3740<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>HR:</b> Hazard Ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_416473753410884319" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_416473753410884319</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> There was considerable clinical heterogeneity with respect to radiotherapy dose, technique and use of quality assurance procedures. However, the techniques employed delivered a dose that was the same or higher in the APBI/PBI arm than the WBRT arm, which should mean the local recurrence‐free survival is better or at least the same.<br/><b>b.</b> To calculate the control risk for LR‐FS, we used the number free from local recurrence at five years.<br/><b>c.</b> Studies that contributed data for this outcome at five years: Livi, ELIOT, IMPORT, GEC‐ESTRO, Polgar, TARGIT and RAPID.<br/><b>d.</b> Downgraded one level for imprecision: confidence intervals failed to exclude harms that are clinically important and clinically unimportant.<br/><b>e.</b> One study (which contributed 47% of study weight for this outcome) was at low risk of detection bias.<br/><b>f.</b> Studies that contributed data at five years: Polgar, Livi, TARGIT, Rodriguez, RAPID and GEC‐ESTRO.<br/><b>g.</b> Downgraded one level for risk of detection bias and heterogeneity.<br/><b>h.</b> To calculate the control risk for overall survival, we used the number alive at five years.<br/><b>i.</b> To calculate the control risk for cause‐specific survival, we used the number free from breast cancer death at five years.<br/><b>j.</b> Studies that contributed data at five years: Livi, ELIOT, IMPORT, GEC‐ESTRO, Polgar and RAPID.<br/><b>k.</b> Downgraded one level for detection bias and imprecision: fewer than 300 events contributed to this outcome and confidence intervals failed to exclude both clinically important benefits and harms.<br/><b>l.</b> Confidence intervals failed to exclude clinically important benefits and unimportant harms.<br/><b>m.</b> Five studies contributed data to control event‐free rate at five years (ELIOT, GEC‐ESTRO, IMPORT, Livi and Polgar).<br/><b>n.</b> To calculate the control risk for distant metastasis‐free survival, we used the number free from metastasis at five years.<br/><b>o.</b> Downgraded one level for detection bias and imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of Findings Table ‐ PBI?APBI compared to WBRT for early breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Harvard Cosmetic Score</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cosmetic score</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excellent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Harvard Cosmetic Score</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">EORTC/RTOG CTCAE</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>RTOG CTC</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade II</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade III</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade IV</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follicular, faint or dull erythema/epilation/dry desquamation/decreased sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tender or bright erythema, patchy moist desquamation/moderate oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confluent, moist desquamation other than skin folds, pitting oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulceration, haemorrhage, necrosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late skin toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slight atrophy, pigmentation change, some hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patchy atrophy, moderate telangiectasia, total hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marked atrophy, gross telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulceration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late subcutaneous fibrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slight induration, loss of subcutaneous fat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate fibrosis (asymptomatic)</p> <p>&lt; 10% linear field contraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe induration, loss of subcutaneous tissue, linear contraction &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulceration</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organisation for Research and Treatment of Cancer; RTOG CTC: Radiation Therapy Oncology Group Common Toxicity Criteria. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">EORTC/RTOG CTCAE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">NCI CTC 3.0</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Toxicity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade 4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration (subcutaneous fibrosis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased density on palpation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate increase in density, not interfering with ADL; marked increase in density and firmness on palpation with or without minimal retraction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysfunction interfering with ADL; very marked density, retraction or fixation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many and confluent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain mild, not interfering with function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate pain; pain or analgesics interfering with function, but not with ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe pain; pain or analgesics interfering with ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ADL: activities of daily living; NCI CTC: National Cancer Institute Common Toxicity Criteria. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">NCI CTC 3.0</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">EORTC/RTOG CTCAE Version 3.0</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade II</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade III</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade IV</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Grade V</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild, not interfering with function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate/analgesics, interferes with function, but not ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe or interferes with ADL, or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many or confluent, or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute skin toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faint erythema or dry desquamation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate‐to‐brisk erythema, patchy moist desquamation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moist desquamation not limited to creases or skin folds, bleeding subsequent to minor trauma or abrasion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin necrosis or full dermal thickness ulceration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration/fibrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased density on palpation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate functional impairment, not interfering with ADL, increased density and firmness on palpation with or without minor retraction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interferes with ADL, very marked increased density, retraction or fixation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ADL: activities of daily living; CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organisation for Research and Treatment of Cancer; RTOG: Radiation Therapy Oncology Group. </p> <p><a href="./references#CD007077-bbs2-0036" title="National Institute of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Effects Version 3.0. ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed 27July 2020).">CTCAE 2006</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">EORTC/RTOG CTCAE Version 3.0</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">RTOG/EORTC CTCAE Version 4.0</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade II</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade III</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade IV</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Grade V</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subcutaneous fibrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild induration, can move skin parallel to the plane (sliding) and perpendicular to the plane (pinching up) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate induration, can slide, cannot pinch up skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe induration cannot slide or pinch skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10 % of body surface area</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 10% of body surface area, psychosocial impact</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate, not limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe, limiting self‐care ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ADL: activities of daily living; CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organisation for Research and Treatment of Cancer; RTOG: Radiation Therapy Oncology Group.<br/><a href="./references#CD007077-bbs2-0037" title="National Institute of Health and Human Services, National Cancer Institute. Common Toxicity Criteria for Adverse Effects, Version 4.0. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (accessed 27 July 2020).">CTCAE 2009</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">RTOG/EORTC CTCAE Version 4.0</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Fat necrosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Grade</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No fat necrosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic fat necrosis (only radiological or cytological findings, or both)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic fat necrosis not requiring medication (palpable mass with or without mild pain) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic fat necrosis requiring medication (palpable mass with significant pain)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic fat necrosis requiring surgical intervention</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Fat necrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Participants</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Stage</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Margins</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tumour size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nodal status</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 2000, &lt; 40 years excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unifocal tumour, pT1N0‐1miM0, Grade I or II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 2.0 cm</p> <p>(&lt; 2 mm: 1/258, ≥ 2 mm: 246/258 or had no tumour at ink: 11/258)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48–75 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Early breast cancer," "suitable for breast conservation"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 2.5 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD if SNBx positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 40 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative, ≥ 5 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 2.5 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLE or quadrantectomy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1 and small T2N0‐1M0 invasive breast cancer, suitable for BCS, available for 10 years' follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1 mm</p> <p>Re‐excision strongly advised for close or positive margins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 40 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DCIS<sup>a</sup> or invasive breast cancer </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative axillary nodal involvement including micrometastasis (&gt; 0.2 mm or positive cells only identified on IHC as determined by sentinel node biopsy; axillary node dissection or clinical examination for DCIS only. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive ductal carcinoma <i>(</i>pT1‐2cNO MO), unifocal tumour, Grade I or II </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 3 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive breast cancer pT1‐2pN0 who have &lt; 1% annual risk of local recurrence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0–3 nodes positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 40 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stage 0, I or II pN0/pNmi breast cancer (including DCIS) no vascular invasion, unifocal or unicentric disease only, no LVINote: 60/1184 (5%) participants had DCIS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 mm in invasive disease, 5 mm in DCIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lesions &lt; 3 cm in diameter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Node negative, for DCIS alone: sentinel node biopsy optional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WLE or quadrantectomy, level I–II axillary dissection, removing ≥ 6 (preferably 10 lymph nodes) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T0‐2N0‐1M0 DCIS or invasive breast cancer</p> <p>Note: 531/4216 (12%) participants had DCIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative: "free of cancer, including DCSI"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lesions &lt; 3 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 involved nodes permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lumpectomy</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>AD: axillary dissection; BCS: breast‐conserving surgery; DCIS: ductal carcinoma in situ; IHC: immunohistochemistry; LVI: lymphovascular invasion; SNBx: sentinel node biopsy; WLE: wide local excision.<br/><sup>a</sup>366/2135 participants had DCIS. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>RT quality assurance</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>RT technique</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>PIB/APBI target volume definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postimplant CT scans were performed<br/>for 17/87 (20%) participants to document PTV coverage </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interstitial brachytherapy (88/128)</p> <p>EBRT using photons (40/128)</p> <p>2‐dimensional CT‐based<br/>treatment planning was used for all participants </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTV: excision cavity delineated by the surgical clips + 2 cm isotropic margin. For interstitial therapy: if electrons were used, 6–15 MeV were used to treat the cavity with a 2 cm margin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intraoperative electrons 6–9 MeV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV: quote: "decided according to the site and size of the tumour. The energy of the electron beams was selected according to the thickness of the gland measured by a graduated needle" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EBRT (IMRT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV = +1 cm isotropic margin around surgical clips</p> <p>PTV = CTV +10 mm isotropic margin<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intraoperative kV RT</p> <p>3D‐CRT for WBRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The target volume was the tumour cavity<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EBRT (3D‐CRT)</p> <p>APBI: 3–5 non‐coplanar fields</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV = tumour bed on CT (surgical clips plus a 1‐cm margin inside breast<br/>tissue) </p> <p>PTV = CTV +1 cm isotropic margin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EBRT (3D‐CRT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTV was defined by contouring the same quadrant as the primary tumor site<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Field‐in‐field IMRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumour bed, surgical clips<sup>g</sup> recommended </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDR or PDR multicatheter brachytherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBI: tumour bed<sup>i</sup> +2 cm isotropic margin </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quote: "Every institution's RT facilities were quality assessed and each case of APBI was centrally reviewed for RT quality." Benchmarking performed with "dummy run" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDR brachytherapy<sup>j</sup> </p> <p>APBI EBRT: 3D‐CRT<sup>k</sup> (IMRT not permitted). </p> <p>WBRT: 3D‐CRT (IMRT not permitted)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No RNI permitted</p> <p>WBRT: entire ipsilateral breast</p> <p>APBI: CTV = cavity = PTV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RT quality assurance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RT technique</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Target volume definition</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>3D‐CRT: 3‐dimensional conformal radiotherapy; APBI: accelerated partial breast irradiation; CRT: conformal radiotherapy; CT: computer tomography; CTV: clinical target volume; EBRT: external beam radiotherapy; HDR: high‐dose rate; IMRT: intensity‐modulated radiotherapy; PDR: pulsed‐dose rate; PIB: partial breast irradiation; PTV: planning target volume; RNI: regional nodal irradiation; RT: radiotherapy; WBRT: whole breast radiotherapy. </p> <p><sup>a</sup>The surgeons were requested to place clips at the borders of the surgical bed, using a minimum of four clips. CTV was drawn on a planning CT (0.3 mm slices) with a uniform 1 cm margin around the surgical clips, then a 1 cm margin added to construct the PTV.<br/><sup>b</sup>For the WBRT component of <a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a>, as long as treating centres conformed to a formal quality management system issued by the International Standards Organisation, no additional quality assurance was required. For the APBI, quality assurance was performed according to the manufacturer's instructions and the resulting data to be made available to the trials centre. Data were submitted either annually or after every 50th participant treated with Intrabeam.<br/><sup>c</sup>Quote: "The appropriately sized (1.5–5.0 cm diameter) applicator is placed in the tumour bed using a meticulous surgical technique, including a carefully inserted purse‐string suture that ensures that breast tissues at risk of local recurrence receive the prescribed dose while skin and deeper structures are protected. Radiation is delivered over 20–45 min to the tumour bed. The surface of the tumour bed typically receives 20 Gy that attenuates to 5–7 Gy at 1 cm depth."<br/><sup>d</sup>Before study opening, physicians' tumour bed contouring and centres' APBI planning were credentialed. Centres completed real‐time review of at least 10 APBI patient cases before treatment and final review of all patient cases.<br/><sup>e</sup>To avoid interobserver variability, this was performed by the same radiation oncologist. Surgical clips were not available at the institution at the time.<br/><sup>f</sup>Baseline questionnaire completed by centre, UK Radiotherapy Trial Quality Assurance (RTQA) validated the treatment technique, a phantom was used, all plans and data sets collected and stored at RTQA, every 10th enrolled participant was selected at random to have thermo‐luminescent dosimetry measurements, which were sent to RTQA.<br/><sup>g</sup>If no clips had been inserted, ultrasound, magnetic resonance imaging or CT was used. If no localisation procedure had been done, study entry was permitted if the clinician was confident that clinical localisation was accurate.<br/><sup>h</sup>Both pre‐ and postimplant assessment of geometry using CT, dose prescription and calculations were in accordance with International Commission of Radiation Units and Measurements (ICRU) 58 and strict dose volume histogram and dose maximums were mandated, the post‐hoc quality assurance requirements were clearly detailed in the study protocol (<a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a>).<br/><sup>i</sup>Tumour bed localised using clips, preoperative mammographic and ultrasound imaging and planning scan.<br/><sup>j</sup>HDR multicatheter, HDR single entry (MammoSite single‐lumen, MammoSite multi‐lumen, Contura multi‐lumen balloon).<br/><sup>k</sup>10 fractions, given with six‐hour gap on five treatment days within an eight‐day period. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Brachytherapy cosmetic score</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Score</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perfect symmetry, no visible distortion or skin changes and no visible catheter entry/exit sequelae </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slight skin distortion, retraction or oedema, any visible telangiectasia, any visible catheter entry/exit scar or mild hyperpigmentation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate distortion of the nipple or breast symmetry, moderate hyperpigmentation, or prominent skin retraction, oedema or telangiectasia </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Marked distortion, oedema, fibrosis or severe hyperpigmentation</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Brachytherapy cosmetic score</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0011"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Radiotherapy doses prescribed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>PBI/APBI dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Fraction size (Gy)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>EQD<sub>2</sub> PBI/APBI</b> </p> <p><b>alpha/beta = 4</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Control dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Fraction size (Gy)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>EQD<sub>2</sub> Control</b> </p> <p><b>alpha/beta = 4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 Gy at surface of the applicator (attenuated to 5–7 Gy at 1 cm) (APBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 at cavity surface</p> <p>12.8 at 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 Gy at cavity</p> <p>surface</p> <p>12.8 Gy at 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40–56 Gy/20–28 fractions ± 10–16 Gy boost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40–56 Gy ±</p> <p>10–16 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 Gy/5 daily fractions EBRT IMRT. 100% of the PTV was covered by 95% of the prescribed dose </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy/25 fractions + 10 Gy/5 fractions boost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 + 10 = 60 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5 Gy/10 fractions twice daily (with 6‐hour gap)</p> <p>Dose‐evaluation volume (that part of PTV within the breast) received 95–107% of prescription dose </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.4 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy/25 fractions or 42.5 Gy/16 fractions ± boost (10 Gy/4–5 fractions) based on criteria such as young age or close margins, prespecified by centre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 or 2.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy or 47.1 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.5 Gy/10 fractions twice daily (with 6‐hour gap) (APBI). PTV covered by ≥ 95% of prescribed dose, with &lt; 105% hot spot </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.48 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 Gy/24 fractions ± 10 Gy/5 fractions boost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 ± 10 = 48–58 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 × 5.2 Gy HDR (APBI) or 50 Gy/25 fractions (PBI)<br/>Women unsuitable for HDR had 6–15 MeV beam to tumour bed plus 2 cm margin (field size defined using CT‐planning or simulation films) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 or 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.5 Gy or 50 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy/25 fractions (3D‐CRT was not used)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.3 Gy/7 fractions or 32 Gy/8 fractions HDR twice daily or 50 Gy at 0.6–0.8 Gy/hour pulses (1 pulse per hour, 24 hours per day) PDR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7–8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.64–42.67 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.0–50.4 Gy to a reference point + 10 Gy/5 fractions boost. Electron dose was prescribed to the point of maximum dose on the beam axis (D<sub>max</sub>), ensuring the 85% isodose encompassed the tumour bed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8–2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.72–50 + 10 = 58.72–60 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 Gy/1 fraction at 90% using 6–9 MeV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 Gy/25 fractions + 10 Gy/5 fractions boost (using electrons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 + 10 Gy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 Gy/15 fractions (EBRT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 Gy/15 fractions</p> <p>36 Gy/15 fractions + boost 40 Gy/15 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.72</p> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.23</p> <p>38.4 + 45.23</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>3D‐CRT: 3‐dimensional conformal radiotherapy; APBI: accelerated partial breast irradiation; CT: computer tomography; EBRT: external beam radiotherapy; EQD<sub>2</sub>: equivalent dose in 2 Gy fractions; Gy: Gray; HDR: high‐dose‐rate; IMRT: intensity‐modulated radiotherapy; MeV: mega electron volt; PBI: partial breast irradiation; PDR: pulsed‐dose rate; PTV: planning target volume. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Radiotherapy doses prescribed</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007077-tbl-0012"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Stud</b>y </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mammography</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Radiotherapy toxicity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Patient‐reported outcomes (PRO)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cosmesis</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0006" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4 year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):724-31. LoveyT , FodoflJ , SulyokZ , Takacsi-NagyZ , PolgárC . Incidence of fat necrosis following whole breast radiotherapy versus partial breast irradiation: results of the Budapest partial breast irradiation trial. Radiotherapy and Oncology2005;75:S3. PolgárC , FodorJ , MajorT , NémethG , LöveyK , OroszZ , et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast cancer – 5-year results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2007;69(3):694-702. PolgárC , FodorJ , MajorT , SulyokA , KáslerM . Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiotherapy and Oncology2013;108(2):197-202. PolgárC , MajorT , FodorJ , SulyokZ , Takacsi-NagyZ , NemethG . Breast-conserving therapy with partial or whole breast radiation: 10-year results of the Budapest randomized trial. Radiotherapy and Oncology2012;103(Suppl 2):S35. PolgárC , MajorT , SulyoZ , Takacsi-NagyZ , FodorJ . Toxicity and cosmetic results of partial vs whole breast irradiation: 10-year results of a randomized trial. Radiotherapy and Oncology2014;111:S60. PolgárC , SulyokZ , FodorJ , OroszZ , MajorT , Takácsi-NagyZ , et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. Journal of Surgical Oncology2002;80(3):121-8, discussion 129. PolgaŕC , MajorT , FodorJ , NemethG , OroczZ , SulyokZ , et al. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumour bed boost after breast-conserving surgery: seven-year results of a comparative study. International Journal of Radiation Oncology, Biology, Physics2004;60(4):1173-81. WilliamsN , KurylcioA , JankiewiczM , RomanekJ , PolkowskiW , MichalopoulosN , et al. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland. European Journal of Gynaecological Oncology2017;38(6):867-70. ">Polgár 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6 months, then annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute: CTCAE<sup>a</sup> </p> <p>Late: EORTC/RTOG<sup>b</sup> and LENT‐SOMA<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Harvard Cosmetic Score<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0001" title="FastnerG , ReitsamerR , SedlmayerF . Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlentherpie und Onkologie2014;190(4):422-4. NCT01849133. Randomized clinical trial: comparison between quadrantectomy followed by external fractionated radiotherapy and quadrantectomy associated with intraoperative radiotherapy in women &gt;= 48 years of age affected by early-stage breast carcinoma. clinicaltrials.gov/ct2/show/NCT01849133 (first received 8 May 2013). VeronesiU , OrecchiaR , MaisonneuveP , RotmenszN , SangelliC , LuiniA , et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised equivalence trial. Lancet Oncology2013;14(13):1269-77. ">ELIOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LENT‐SOMA<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0004" title="LiviL , BuonamiciFB , SimontacchiG , ScottiV , FambriniM , CompagnucciA . Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized controlled trial. International Journal of Radiation Oncology, Biology, Physics2010;77(2):509-15. LiviL , MeattiniI , MarrazzoL , PallottaS , SimontacchiG , SaievaC , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: 5-year survival results of a phase 3 randomized trial. Cancer Research2015;75(9 Suppl):S5-03. LiviL , MeattiniI , MarrazzoL , SimontacchiG , PallottaS , SaievaC , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year analysis of a phase 3 randomised controlled trial. European Journal of Cancer2015;51(4):451-63. [DOI: 10.1016/j.ejca.2014.]LiviL , MeattiniI , SaievaC , FranceschiniD , MeacciF , FranzeseF . Accelerated partial breast irradiation with IMRT: 3-years interim analysis of a phase III randomised clinical trial. Radiotherapy and Oncology2012;103(Suppl 1):S51. LiviL , MeattiniI , SaievaC , ScottiV , De LucaC , MeacciF , et al. Accelerated partial breast irradiation with intensity-modulated radiotherapy (IMRT): the Florence phase III randomized clinical trial at 3 years median follow-up. European Journal of Cancer2012;48(Suppl 1):S183. MeattiniI , MarrazzoC , SaievaS , PallottaG , SimontacchiV , ScottiI , et al. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomised trial. Radiotherapy and Oncology2015;115:S20. MeattiniI , MarrazzoL , Di BrinaL , MangoniM , MeacciF , BendinelliB , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomised phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , MarrazzoL , SaievaC , DesideriI , ScottiV , SimontacchiG , et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. Journal of Clinical Oncology2020;38(35):4175-83. [DOI: 10.1200/JCO.20.00650]MeattiniI , MarrazzoL , ZaniM , PaiarF , PallottaS , SimontacchiG , et al. Four‑dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial. Radiologica Medicina2015;120(11):1078-82. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , MiccinesiG , SaievaC , DesideriI , Di Brina, FrancoliniG , et al. Accelerated partial breast irradiation versus whole breast irradiation: short term quality of life results from a phase 3 trial. Cancer Research2016;76(4):S1. MeattiniI , SaievaC , DesideriI , De LucaC , ScottiV , MiccinesiG , et al. Accelerated partial breast irradiation versus whole breast radiotherapy: quality of life results from a phase 3 randomized trial and focus on patients aged 70 years or older. European Journal of Cancer2016;2:S47. MeattiniI , SaievaC , DesideriI , SimontacchiG , MarrazzoL , ScocciantiS , et al. Accelerated partial breast irradiation for luminal-a breast cancer: analysis from a phase 3 trial. Radiotherapy and Oncology2016;119(Suppl 1):S242. MeattiniI , SaievaC , LucidiS , Lo RussoM , ScottiV , DesideriI , et al. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Cancer Research2019;80:4. MeattiniI , SaievaC , MarrazzoL , Di BrinaL , PallottaS , MangoniM , et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Research and Treatment2015;153(3):539-47. MeattiniI , SaievaC , MiccinesiG , DesideriI , FrancoliniG , ScottiV , et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer2017;76:17-26. MeattiniI , SaievaC , MiccinesiG , DesideriI , MarrazzoL , LoiM , et al. Health-related quality of life analysis from the accelerated partial breast irradiation IMRT-Florence phase 3 trial: impact of age and scores trend over time. European Journal of Cancer2017;72(Suppl 1):S8. NCT02104895. Randomised phase II trial of accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation. clinicaltrials.gov/ct2/show/NCT02104895 (first received 7 April 2014). ">Livi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute and late: EORTC/RTOG<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC QLQ‐C30<sup>e</sup> </p> <p>QLQ‐BR23 breast cancer module<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Harvard Cosmetic Score<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0009" title="Abo-MadyanY , WelzelG , SperkE , NeumaierC , KellerA , ClausenS , et al. Intraoperative (IORT) versus whole-breast radiation therapy (WBRT) for early breast cancer: single-center results from the randomized phase 3 TARGIT-A trial A. International Journal of Radiation Oncology, Biology, Physics2016;96(2):E16-17. AndersenKG , GärtnerR , KromanN , FlygerH , KehletH . Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast2012;21(1):46-9. Anon. Erratum: radiotherapy for breast cancer, the TARGIT-A trial (The Lancet (2014) 383(9930) (1716). Lancet2015;385(9976):1396. Anon. Erratum: targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. BaumM , JosephDJ , TobiasJS , WenzFK , KeshtgarMR , AlvaradoM , et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: first report of a randomized controlled trial at 10-years maximum follow-up. Journal of Clinical Oncology2010;28(18 Suppl):Abstract LBA517. BaumM . TARGIT-A trial (targeted intraoperative radiotherapy): updated analysis of local recurrence. Breast2013;22:S95. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , VaidyaJ , et al. Cosmesis and breast-related quality of life outcomes after intraoperative radiation therapy for early breast cancer: a substudy of the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2016;96(1):55-64. CoricaT , NowakA , SaundersC , BulsaraM , TaylorM , WilliamsN , et al. Cosmetic outcome as rated by patients, doctors, nurses and BCCT core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology2018;13(1):68. CoricaT , NowakA , SaundersM , BulsaraM , TaylorM , JosephD . Patient preferences for adjuvant radiotherapy – outcomes from the TARGIT – a study in Western Australia. Asia-Pacific Journal of Clinical Oncology2016;12(S5):106-7. HolmesDR , BaumM , JosephD . The TARGIT trial: targeted intraoperative radiation therapy versus conventional postoperative whole-breast radiotherapy after breast-conserving surgery for the management of early-stage invasive breast cancer (a trial update). American Journal of Surgery2007;194(4):507-10. JosephD . TARGIT. Radiotherapy and Oncology2012;103 Suppl 2:S4. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2013;31(15):S1. KeshtgarM , WilliamsN , CoricaT , BulsaraM , SaundersC , FlygerH , et al. Cosmetic outcome is better after intraoperative radiotherapy compared with external beam radiotherapy: an objective assessment of patients from a randomized controlled trial. Cancer Research2013;73(24S):5-14. KeshtgarMR , WilliamsNR , BulsaraM , SaundersC , FlygerH , CardosoJS , et al. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment2013;140(3):S19. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , BulsaraM , on behalf of the TARGIT Trialists' Group. Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy compared with external beam radiotherapy for treatment of early breast cancer: an objective assessment of patients from a randomized controlled trial. Proceedings of ASTRO2011;80:S225. KeshtgarMR , WilliamsNR , CoricaT , SaundersC , JosephDJ , on behalf of the TARGIT Trialists' Group. Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: an objective assessment of patients from a randomized controlled trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract 570. NCT00983684. Comparison of intra-operative radiotherapy with post-operative radiotherapy for women with early breast cancer (TARGIT). clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [NCT00983684]NeumaierC , WelzelG , KellerA , Abo-MadyanY , SperkE , GerhardtA . Targeted intraoperative radiotherapy in elderly patients (TARGIT-E) with early breast cancer; first safety analysis after 80 treated patients. Strahlentherapie und Onkologie2015;191(1S1):S46. VaidyaA , VaidyaP , BothB , Brew-GravesC , BulsaraM , VaidyaJ . Health economics of targeted intraoperative radiotherapy (TARGIT-IORT) for early breast cancer: a cost-effectiveness analysis in the United Kingdom. BMJ Open2017;7(8):e014944. VaidyaA , VaidyaP , BothB . Cost-utility analysis (CUA) of targeted intraoperative radiotherapy alone (TARGIT-A) in the Brazilian early breast cancer patients. Value in Health2017;20(9):A584. VaidyaJ , BulsaraM , WenzF , JosephD , SaundersC , MassarutS , et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT – a trial of targeted intraoperative radiation therapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics2015;92(3):491-7. VaidyaJ , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. Fewer non-breast cancer deaths in TARGIT-A trial: systemic benefit of TARGIT or lack of EBRT toxicity. Breast2013;22:S97. VaidyaJ , BulsaraM , WenzF , TobiasJ , JosephD , MassarutS , et al. Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT A trial. Radiotherapy and Oncology2015;115(S1):232-3. VaidyaJ , WenzF , BulsaraM , TobiasJ , JosephD , SaundersC , et al. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment2016;20(73):1-188. VaidyaJS , BulsaraM , BaumM , WenzF , MassarutS , PigorschS , et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ2020;370(2836):1-15. [DOI: 10.11.36.bmj.m2836]VaidyaJS , BulsaraM , WenzF , MassarutS , JosephD , TobiasJ , et al. The lower non-breast cancer mortality with TARGIT in the TARGIT – a trial could be a systemic effect of TARGIT on tumor microenvironment. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S240. VaidyaJS , JosephD , HilarisBS , TobiasJS , HoughtonI , KeshtgarM , et al. Targeted intraoperative radiotherapy for breast cancer (TARGIT): an international trial. Radiotherapy and Oncology2002;64(S1):S136. VaidyaJS , JosephDJ , TobiasJS , BulsaraM , WenzF , SaundersC , et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet2010;376(9735):91-102. VaidyaJS , TobiasJS , BaumM , WenzF , Kraus-TiefenbacherU , D'SouzaD , et al. TARGeted Intraoperative radiotherapy (TARGIT): an innovative approach to partial-breast irradiation. Seminars in Radiation Oncology2005;15(2):84-91. VaidyaJS , WenzF , BulsaraM , MassarutS , TobiasJ , WilliamsN , et al. Omitting whole breast radiation therapy did not increase axillary recurrence in the TARGIT-A trial. International Journal of Radiation Oncology, Biology, Physics2013;87:2S. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Erratum. Lancet2014;383(9917):602. VaidyaJS , WenzF , BulsaraM , TobiasJS , JosephDJ , KeshtgarM , et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT – a randomised trial. Lancet2014;383(9917):603-13. VaidyaJS . In favour of partial breast irradiation in selected patients and a well-directed intraoperative boost. Breast2006;15(5):581-3. VaidyaJS . Partial breast irradiation using targeted intraoperative radiotherapy (TARGIT). Nature Clinical Practice Oncology2007;4(7):384-5. WelzelG , BochA , BlankE , Kraus-TeifenbacherU , KellerA , HermannB , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Proceedings of ASTRO2011;81:S206-7. WelzelG , BochA , SperkE , HofmannF , Kraus-TiefenbacherU , GerhardtA , et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology2013;8:9. WenzF , VaidyaJS , PigorschS , FeyerP , RoedelC , BelkaC , et al. Local recurrence and survival for the German centers in the TARGIT-A (TARGeted Intraoperative Radiation Therapy – Alone) trial. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S241. ">TARGIT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute: nil</p> <p>Late: EORTC/RTOG,<sup>b</sup> LENT‐SOMA,<sup>c</sup> CTCAE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC QLQ‐C30<sup>e</sup> </p> <p>QLQ‐BR23 breast cancer module</p> <p>Body‐image scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinician and nurse assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0007" title="ISRCTN62704822. 3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial. www.isrctn.com/ISRCTN62704822 (first received 24 June 2008). NCT00282035. RAPID: randomized trial of accelerated partial breast irradiation. clinicaltrials.gov/ct2/show/NCT00282035 (first received 25 January 2006). OlivottoIA , WhelanTJ , ParpiaS , KimDH , BerrangT , TruongPT , et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology2013;31(32):4038-45. PetersonD , TruongPT , ParpiaS , OlivottoIA , BerrangT , KimDH . Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis. International Journal of Radiation Oncology, Biology, Physics2015;91(5):968-76. SouchonR . Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and cancer: the multicentric randomised RAPID trial. Strahelentherapie und Onkologie2020;196(6):579-2. WhelanT , JulianJ , LevineM , BerrangT , KimDH , GuCS , et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research2019;79(4 Suppl):GS4-03. WhelanTJ , JulianJA , BerrangTS , KimD , GermainI , NicholAM , et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet2019;394(10215):2165-72. ">RAPID</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute and late: NCI version 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC QLQ‐C30<sup>e</sup> </p> <p>QLQ‐BR23 breast cancer module</p> <p>Body‐image scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC/RTOG Rating System<sup>g</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0008" title="RodríguezN , SanzX , DengraJ , ForoP , MembriveI , ReigA , et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics2013;87(5):1051-7. RodríguezN , SanzX , ForoP , ReigA , MembriveI , LozanoJ , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast radiation therapy using 3D-CRT. Radiotherapy and Oncology2012;103(Suppl 1):S400. RodríguezXS , ForoP , ReigA , LacruzM , LozanoJ , MembriveI , et al. Phase III study comparing accelerated partial breast irradiation vs whole breast irradiation using 3D-CRT. Interim analysis. Radiotherapy and Oncology2008;88:S201. Rodriguez de DiosN , SanzX , DengraJ , ForoP , ReigA , MembriveI , et al. Interim cosmetic results and toxicity using 3D conformal external beam radiation therapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics2012;84:3S. ">Rodríguez</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline 6 months after RT than annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late: EORTC/RTOG<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Harvard Cosmetic Score<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0003" title='BhattacharjeeA , ChakrabortyS . In regard to Livi et al. "Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial". European Journal of Cancer2015;51(11):1476. BhattacharyaIS , HavilandJS , HopwoodP , ColesCE , YarnoldJR , BlissJM , et al. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and Oncology2019;134:220-30. BhattacharyaIS , HavilandJS , KirbyAM , KirwanCC , HopwoodP , YarnoldJR , et al, IMPORT Trialists. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology2019;37(4):305-17. [DOI: 10.1200/JCO.18.00982]BhattacharyaJS . Concordance of patient reported outcomes with clinician and photographic assessments in IMPORT LOW. Radiotherapy and Oncology2018;3:S79. BhattacharyaLS , HavilandJS , HopwoodP , KirbyAM , YarnoldJR , BlissJM . A longitudinal analysis of patient reported outcomes over 5 years in the IMPORT LOW (partial breast radiotherapy after breast conservation surgery) phase III randomised controlled trial. European Journal of Cancer2018;92:S3. ColesC , AgrawalR , Ah-SeeML , AlgurafiH , AlhassoA , BruntAM , et al. Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). European Journal of Cancer2016;2:S4. ColesC , DonovanE , VenablesK , RowlingsC , MaylexH , BentzenS , et al. Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial). British Journal of Cancer2004;91(Suppl 1):S80. ColesC , GriffinC , KirbyA , AgrawalR , AlhassoA , BhattacharyaI , et al. Partial breast irradiation after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology2017;123:S162. ColesC , GriffinC , KirbyA , TitleyJ , TsangY , HarnettA , et al. Partial breast radiotherapy for women with early breast cancer: first analysis of late cosmesis adverse events from IMPORT LOW (CRUK/06/003). European Journal of Cancer2014;50:0454. ColesC , YarnoldJ . The IMPORT trials are launched (September 2006). Clinical Oncology2006;18(8):587-90. ColesCE , GriffinCL , KirbyAM , TitleyJ , AgrawalRK , AlhassoA , et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet2017;390(10099):1048-60. [DOI: 10.1016/S0140-6736(17)31145-5]ColesCE , WilsonCB , CummingJ , BensonJR , ForouhiP , WilkinsonJS . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. European Journal of Surgical Oncology2009;35(6):578-82. [DOI: 10.1016/j.ejso.2008.09.005]NCT00814567. Radiation therapy in treating women with early-stage breast cancer who have undergone breast conservation therapy. clinicaltrials.gov/ct2/show/NCT00983684 (first received 24 September 2009). [CDR0000629768, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISRCTN12852634, EU-20896]'>IMPORT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually 1–5 years,</p> <p>3 yearly to 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic rib fracture</p> <p>and lung fibrosis</p> <p>Ischaemic heart disease</p> <p>recorded at 1, 2, 5 and</p> <p>10 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC QLQ‐C30<sup>e</sup> </p> <p>QLQ‐BR23 breast cancer module</p> <p>Body‐image scale</p> <p>protocol‐specific questions<sup>h</sup> </p> <p>HADS scale</p> <p>EuroQol EQ‐5D‐3L health status questionnaire</p> <p>at baseline; 6 months; 1, 2 and 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐ and</p> <p>clinician‐assessed<sup>i</sup> </p> <p>Photos<sup>j</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0002" title="European Brachytherapy Breast Cancer GEC-ESTRO Working Group. Interstitial brachytherapy alone versus external beam radiation therapy after breast conserving surgery for low risk invasive carcinoma and low risk duct carcinoma in-situ (DCIS) of the female breast (Study protocol). clinicaltrials.gov Accessed 20/08/21. NCT00402519. APBI versus EBRT therapy after breast conserving surgery for low-risk breast cancer. clinicaltrials.gov/ct2/show/NCT00402519 (first received 22 November 2006). OttOJ , StrnadV , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiotherapy and Oncology2016;120(1):119-23. [DOI: 10.1016/j.radonc.2016.06.019]PolgárC , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology2017;18(2):259-68. [DOI: 10.1016/S1470-2045(17)30011-6]PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Incidences of late toxicities and cosmetic results after accelerated partial breast irradiation with multi-catheter brachytherapy or whole breast irradiation: 5-year results of the GEC-ESTRO Phase III APBI trial brachytherapy. World Congress of Brachytherapy Conference Publication2016;15:S47. PolgárC , StrnadV , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial. Radiotherapy and Oncology2016;2016:S230. SchäferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology2018;19:834-44. SchaferR , StrnadV , PolgárC , UterW , HildebrandtG , OttOJ , et al. QOL after APBI (multicatheter brachytherapy) versus WBI: 5-year results, phase 3 GEC-ESTRO Trial. Radiotherapy and Oncology2018;127(S1):173-4. StrnadV , on behalf of the Groupe Européen de Curietherapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Breast Diseases2016;27(2):153. StrnadV , OttOJ , HildebrandtG , Kauer-DornerD , KnauerhaseH , MajorT , et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet2016;387:229-38. StrnadV , OttOJ , HildebrandtG , PötterR , FietkauR , LyczekJ , et al. First clinical results of the GEC-ESTRO breast WG phase III multicentric PBI/APBI trial. Radiotherapy and Oncology2012;103(Suppl 2):S35-6. StrnadV , PolgárC , OttO , HildebrandtG , Kauer-DornerD , KnauerhaseH , et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy-GECESTRO phase III non-inferiority trial: subanalysis of 5-year results reflecting current GEC-ESTRO and ASTRO recommendations for patient selection. Brachytherapy2016;15:S23. ">GEC‐ESTRO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6, 12, 18, 24 months after radiotherapy then annually for 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fat necrosis measured using Lövey scoring system<sup>k</sup> </p> <p>Physician scored late toxicity</p> <p>Acute radiotherapy toxicity: CTCAE version 3.0<sup>a</sup> </p> <p>LENT‐SOMA<sup>c</sup> </p> <p>Late RT toxicity: EORTC/RTOG<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breast pain and arm lymphoedema measured by CTCAE version 3.0<sup>a</sup> </p> <p>EORTC QLQ‐C30<sup>e</sup> and QLQ‐BR23 at baseline and during follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Harvard Cosmetic Score<sup>d</sup> </p> <p>Physician‐ and patient‐reported</p> <p>Digital photos<sup>l</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007077-bbs2-0005" title="Al-HallaqH , MellL , AdvaniS , Hellman g, NewsteadG , ChmuraS . Magnetic resonance imaging (MRI) identifies multifocal and multicentric disease in breast cancer patients eligible for the NSABP B-39/RTOG 0413 partial breast irradiation (PBI) trial. International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl 1):S179-80. Anonymous. NSABP B-39, RTOG 0413: a randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clinical Advances in Hematology &amp; Oncology2006;4(10):719-21. GaleA , JainAK , VallowLA . The effect of tumor bed location on heart dosimetry for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3 Suppl 1):S735. GanzPA , ReenaS , CecchiniRS , WhiteJR , ViciniFA , Julian TB et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Journal of Oncology2019;37(15 Suppl):508. JainAK , VallowLA , GaleA . Analysis of biologically equivalent lung tissue dose for 3-D conformal partial breast irradiation and whole breast irradiation. International Journal of Radiation Oncology, Biology, Physics2007;69(3):S622-3. JainAK , VallowLA , GaleAA , BuskirkSJ . Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?International Journal of Radiation Oncology, Biology, Physics2009;75(1):82-8. JulianTB , . A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. NSABP B-39/RTOG 0413. Cancer Research2014;71(S24):3. JulianTB , CostantinoJP , ViciniFA , WhiteJR , WinterKA , ArthurDW , et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. Journal of Clinical Oncology2011;29(15 Suppl):1011. KimY , PardaDS , TrombettaMG , ColoniasA , WertsED , MillerL , et al. Dosimetric comparison of partial and whole breast external beam irradiation in the treatment of early stage breast cancer. Medical Physics2007;34(12):4640-8. McCormickB . Partial-breast irradiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. Journal of the National Comprehensive Cancer Network2005;3(3):301-7. NCT00103181. Radiation therapy (WBI versus PBI) in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer. clinicaltrials.gov/ct2/show/NCT00103181 (first received 8 February 2005). TendulkarRD , Chellman-JeffersM , RybickiLA , RimA , KotwalA , MacklisR , et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer2009;115(8):1621-30. [DOI: 10.1002/cncr.24172]ViciniFA , CecchiniRS , WhiteJR , ArthurDW , JulianTB , RabinovitchRA , et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet2019;394(10215):2155-64. ViciniFA , CecchiniRS , WhiteJR , JulianTB , ArthurDW , RabinavichRA , et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. Cancer Research2019;79(4 Suppl):GS4-04. WhiteJR , WinterK , CecchiniRS , ViciniFA , ArthurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1):S3-4. WhiteJR , WinterRS , CecchiniFA , ViciniDW , ArthiurDW , KuskeRR , et al. Cosmetic outcome from post lumpectomy whole breast irradiation (WBI) versus partial breast irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics2019;105(1 Suppl):S3, no. 5. ">NSABP‐B39/RTOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annually</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute radiotherapy toxicity: CTCAE version 4.0</p> <p>Late RT toxicity: CTCAE version 4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physician reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organisation for Research and Treatment of Cancer; EORTC QLQ‐C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; EORTC QLQ‐BR23: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Breast Specific Module; EORTC/RTOG: European Organisation for Research and Treatment of Cancer/Radiation Therapy Oncology Group; HADS: Hospital Anxiety and Depression Scale; LENT‐SOMA: late effects in normal tissues – subjective objective, management and analytic; RT: radiotherapy. </p> <p><sup>a</sup><a href="./references#CD007077-bbs2-0096" title="TrottiA , ColevasAE , SetserA , RuschV , JaquesD , BudachV , et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology2003;13:176-81.">Trotti 2013</a>.<br/><sup>b</sup><a href="./references#CD007077-bbs2-0084" title="Anon. Late effects consensus conference: RTOG/EORTC. Radiotherapy and Oncology1995;35:5-7.">Rubin 1995</a>.<br/><sup>c</sup><a href="./references#CD007077-bbs2-0029" title="Anonymous. LENT SOMA tables. Radiotherapy and Oncology1995;35:17-60.">Anon 1995</a>.<br/><sup>d</sup>Harvard Cosmetic Score uses a four‐point scale: excellent, good, fair or poor (<a href="./references#CD007077-bbs2-0050" title="HarrisJ , LevineM , SvensonG , HellmanS . Analysis of cosmetic results following primary radiation therapy for Stage I and II carcinoma of the breast. International Journal of Radiation Oncology Biology, Physics1979;5:257-61.">Harris 1979</a>).<br/><sup>e</sup>The EORTC QLQ‐C30 includes nine multi‐item scales: five functional (physical, role, emotional, cognitive and social), three symptom scales (fatigue, pain and nausea‐vomiting) and a global health status (GHS) health‐related quality of life scale. There are six single‐item symptom measures: insomnia, appetite loss, constipation, diarrhoea and financial difficulties). The symptom measures are scored on a four‐point scale, with high scores representing a higher symptom burden. The GHS scale is scored using a visual analogue scale: one (very bad) to seven (excellent), so a higher score on GHS or the functional scale is good (<a href="./references#CD007077-bbs2-0026" title="AaronsonNK , BartelinkH , vanDongenJA , vanDamFS . Evaluation of breast conserving therapy: clinical, methodological and psychological perspectives. European Journal of Surgery1998;14:133-40.">Aaronson 1998</a>).<br/><sup>f</sup>The BR23 module uses 23 questions to assess symptoms, treatment adverse effects, body image, sexual function and future perspective using five multi‐item scales. The symptom measures are scored on a four‐point scale, so high scores represent a higher symptom burden. The other aspects are scored so a higher score is better (<a href="./references#CD007077-bbs2-0090" title="SprangersMA , GroenvoldM , ArrarasJL , Franklin J te VeldeA , MullerM , et al. The European Organisation for Research and Treatment of Cancer cancer-specific quality-of-life questionnaire module: first results from a three-country field study. Journal of Clinical Oncology1996;14:2756-68.">Sprangers 1996</a>).<br/><sup>g</sup>The EORTC/RTOG Rating System is a four‐point scale, assessed by trained nurses, physicians and participant‐reported outcomes (<a href="./references#CD007077-bbs2-0026" title="AaronsonNK , BartelinkH , vanDongenJA , vanDamFS . Evaluation of breast conserving therapy: clinical, methodological and psychological perspectives. European Journal of Surgery1998;14:133-40.">Aaronson 1998</a>).<br/><sup>h</sup>Has skin appearance changed, overall breast appearance changed, breast become smaller, breast become harder or firmer to touch, is shoulder stiffness present?<br/><sup>i</sup>Breast shrinkage, distortion, induration, breast oedema, telangiectasia assessed using four‐point scale (not at all, a little, quite a bit and very much). Photos taken at baseline and 2 and 5 years.<br/><sup>j</sup>Photos scored as showing no change, mild or marked change in breast appearance at 2 and 5 years compared with baseline by three observers masked to treatment allocation using a validated consensus method (<a href="./references#CD007077-bbs2-0051" title="HavilandJS , AshtonA , BroadB , GothardL , OwenJR , TaitD , et al. Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer. Clinical Oncology2008;20:497-501.">Haviland 2008</a>).<br/><sup>k</sup><a href="./references#CD007077-bbs2-0066" title="LöveyK , FodorJ , MajorT , SzabóE , OroszZ , SulyokZ , et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy – 4-year results of a randomized trial. International Journal of Radiation Oncology Biology, Physics2007;69:724-31.">Lövey 2007</a>.<br/><sup>l</sup>Digital photos assessed using a validated consensus method by three observers masked to treatment allocation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/full#CD007077-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007077-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Local recurrence‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.03, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.99, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 10 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>(Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.92, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Cosmesis (participant‐reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [1.68, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Cosmesis, physician/nurse‐reported <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.31, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Acute radiotherapy (RT) skin toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.66, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Late RT skin toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [1.63, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Telangiectasia (late RT toxicity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.40 [3.34, 5.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Fat necrosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [1.74, 4.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Subcutaneous fibrosis (late RT toxicity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.07 [3.81, 6.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Breast pain (late RT toxicity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.15, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 New primary tumours in ipsilateral breast, 'elsewhere primary' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [1.55, 5.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Cause‐specific survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Distant metastasis‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.80, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Relapse‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.05, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Locoregional recurrence‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Exp[(O‐E) / V], Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.06, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Subsequent mastectomy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.78, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007077.pub4/references#CD007077-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007077.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007077-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007077-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007077-note-0020">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD007077-note-0022">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD007077-note-0018">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007077-note-0016">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007077-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007077-note-0021">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007077-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007077-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007077\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007077\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007077\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007077\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007077\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007077.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007077.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007077.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007077.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007077.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729516257"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007077.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729516260"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007077.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edeb8eceabd65',t:'MTc0MDcyOTUxNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 